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In the recent years it has become increasingly obvious that multiple sclerosis (MS) is not only 
a white matter (WM) disease of the central nervous system (CNS) but also involves 
frequently and extensively the grey matter (GM) in all MS disease subtypes. Particular 
cortical pathology including demyelinated lesions was reinvestigated in detail by improved 
immunohistochemical staining techniques and new magnetic resonance imaging (MRI) 
acquisition methods. Clinically, MS patients often suffer from physical disability and 
neuropsychological deficits affecting their quality of life. These symptoms were associated 
with GM lesions. Therefore, the pathomechanism(s) leading to GM pathology needs to be 
elucidated for the development of preventative or acute treatments. 
Studying GM pathology requires appropriate animal models reflecting human cortical 
pathology. The most used rodent model in MS research, experimental autoimmune 
encephalomyelitis (EAE), rarely affects the cerebral cortex in ‘conventional’ immunization 
protocols. An EAE model targeting the cortex and reflecting human MS lesions has been 
described in the rat. GM lesions were induced by the injection of proinflammatory cytokines 
in a predetermined cortical area. Due to the lack of useful transgenic rat strains in order to 
study the mechanisms underlying GM pathology, the targeted EAE model needs to be 
established in mice. 
This project focused on the establishment of a targeted cortical EAE mouse model and the 
histopathological characterization. Furthermore, cortical brain tissue of late disease-stage MS 
patients was studied focusing on dendritic pathology. 
Targeted cortical EAE was induced in myelin oligodendrocyte glycoprotein (MOG)-
immunized BiozziABH (antibody high) and F1 offsprings generated from BiozziABH and 
mice on a C57BL6/J background by intracortical injection of TNF-α and IFN-γ. Histological 
analyses revealed widespread subpial demyelination and inflammation in the cortex three 
days after cytokine injection in the affected hemisphere. Within three weeks inflammation 
resolved profoundly and demyelinated lesions showed partial remyelination. Axons remained 
well preserved in lesioned areas and neuronal loss could not be detected in the cortex. 
Furthermore, a method was established that allows detailed analysis of dendritic pathologies 
in mice. 
Cerebral cortex autopsy specimen of progressive MS patients with a long-lasting disease 




chronically demyelinated lesions as well as in the surrounding normal appearing grey matter 
(NAGM). 
In the present project a targeted cortical EAE mouse model was established reproducing key 
hallmarks of GM pathology observed in early-stage MS patients. The model is a useful tool to 
study early events in demyelinated cortex and to investigate therapeutic treatments such as 
increasing remyelination. Furthermore, the global loss of dendritic spines in the cerebral 







In den letzten Jahren ist zunehmend deutlich geworden, dass die Multiple Sklerose (MS) nicht 
nur eine Erkrankung der weißen Substanz des zentralen Nervensystems ist, sondern auch 
häufig und beträchtlich die graue Substanz in allen klinischen Verlaufsformen betrifft. 
Besonders die kortikale Pathologie mit entmarkten Läsionen wurde durch verbesserte 
immunhistochemische Färbetechniken und neuen magnetresonanztomographischen Verfahren 
ausführlicher untersucht. MS-Patienten leiden klinisch oft an körperlichen Beeinträchtigungen 
und neuropsychologischen Defiziten, welche die Lebensqualität beeinflussen. Diese 
Symptome wurden mit Läsionen in der grauen Substanz assoziiert. Mechanismen, die zu 
dieser Pathologie führen, müssen daher aufgeklärt werden um vorbeugende oder akute 
Behandlungen entwickeln zu können. 
Zur pathologischen Untersuchung der grauen Substanz werden angemessene Tiermodelle 
benötigt, welche die humane kortikale Pathologie wiederspiegeln. Das am häufigsten 
verwendete Tiermodell in MS-Studien ist die Experimentelle Autoimmune Enzephalomyelitis 
(EAE), die in ihrem ‘konventionellen’ Immunisierungsprotokoll nur selten den zerebralen 
Kortex betrifft. Ein EAE-Modell mit Einbezug des Kortex, das MS-Läsionen nachahmt, 
wurde in Ratten beschrieben. Hierzu wurden proinflammatorische Zytokine in eine 
vorbestimmte kortikale Region injiziert. Da spezifisch genveränderte Rattenstämme fehlen 
um die Mechanismen der Pathologie in der grauen Substanz zu untersuchen ist es notwendig 
das Tiermodell in Mäusen zu entwickelen. 
Das Ziel dieses Projekts war die Entwicklung eines kortikalen EAE-Mausmodells sowie 
dessen histopathologische Charakterisierung. Desweiteren wurde kortikales Gehirnmaterial 
von MS-Patienten im späten Krankheitsstadium auf dendritische Patholgie untersucht. 
Die kortikale EAE wurde in Myelin Oligodendrozyten Glykoprotein (MOG)-immunisierten 
BiozziABH (hohe Antikörper) und F1 Nachkommen, die aus BiozziABH und Mäusen mit 
einem C57BL6/J-Hintergrund generiert worden sind, durch die intrakortikale Injektion von 
TNF-α und IFN-γ induziert. Histologische Untersuchungen zeigten eine ausgedehnte subpiale 
Entmarkung und Entzündung im Kortex drei Tage nach der Zytokininjektion in der 
betroffenen Hirnhälfte. Die Entzündung ging innerhalb von drei Wochen fast vollständig 
zurück und entmarkte Regionen wiesen teilweise eine Remyelinisierung auf. Axone blieben 
in läsionalen Regionen erhalten und neuronaler Verlust wurde im Kortex nicht beobachtet. 
Desweiteren wurde eine Methode etabliert, die es erlaubt detailliert dendritische Pathologien 




Kortex-enthaltenes Autopsiematerial von progressiven MS-Patienten mit langandauerndem 
Krankheitsverlauf zeigte einen Verlust von dendritischen Dornfortsätzen (Spines) in Neurone, 
die in den unteren korikalen Layern sowohl in chronisch entmarkten Läsionen als auch im 
umliegenden normal erscheinendem Gewebe der grauen Substanz lokalisiert waren.  
Im vorliegenden Projekt wurde ein kortikales EAE-Mausmodell entwickelt, das die humane 
MS-Pathologie der grauen Substanz in frühen Krankheitsstadien wiederspiegelt. Dieses 
Modell ist für Untersuchungen früher Mechanismen im entmarkten Kortex und für die 
Erprobung therapeutischer Behandlungen wie die Erhöhung der Remyelinisierung nützlich. 
Darüberhinaus wurde ein ausgedehnter Verlust dendritischer Dornfortsätze im zerebralen 
Kortex in chronischen MS-Patienten gezeigt, der auf oft beobachtete neuropsychologische 
Defizite zurückgeführt werden könnte. 
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Multiple sclerosis (MS) is a chronic inflammatory demyelinating disease of the central 
nervous system (CNS) typically starting in young adults between 20 and 40 years of age 
(Compston and Coles, 2008; Noseworthy et al., 2000). MS, also known as encephalomyelitis 
disseminata, is the leading cause of nontraumatic permanent neurologic disability in this age 
group in the United States and Europe (Dutta and Trapp, 2007). 
The prevalence of MS varies around the world and is highest in Europe (WHO and MSIF, 
2008). The World Health Organization (WHO) and Multiple Sclerosis International 
Federation (MSIF) estimated in 2008 a total number of people diagnosed with MS of 
approximately 1.3 million worldwide (WHO and MSIF, 2008). Germany belongs to the 
countries with the highest estimated prevalences of MS and in 2008, 122’000 people suffered 
from MS (MSIF). 
The potentially first patient’s description widely accepted representing MS originated from 
the patient’s diaries. From 1822-1848, Sir Augustus d’Este, grandson of King George III, 
described in detail his periodic symptoms including recurring impaired vision, diplopia, 
weakness of the legs, ataxia, spasms, and paralysis (Pearce, 2005). From the early 19
th
 century 
many scientists and physicians studied on the still unnamed nervous disease and contributed 
to the advanced understanding. Working independently Robert Carswell and Jean Cruveilhier 
discovered damage to the CNS in pathological studies (Pearce, 2005). In 1868, the Parisian 
Jean-Martin Charcot first described multiple sclerosis as an independent disease and 
correlated clinical symptoms with pathology of the CNS. He termed the disease “sclérose en 
plaques” (Charcot, 1868). MS is an unpredictable complex disease with diverse clinical, 
immunological and pathological phenotypes. Despite extensive research on this 
heterogeneous disorder the main cause of MS remained undiscovered. Studies in humans and 
animal models reflecting key features of the pathology found in MS patients contributed to 
our understanding resulting to the idea of a CD4
+
 T cell-mediated autoimmune disease 
evolving in genetically susceptible individuals exposed to an environmental trigger. The 
broadening understanding in the recent years that neurodegeneration detrimentally affected 
individuals with MS and the modification of the concept, that MS is not only restricted to the 
white matter (WM) but also involves frequently and extensively the grey matter (GM) yielded 






1.1 Multiple sclerosis 
1.1.1 Etiology of MS 
The cause of MS has not yet been identified and the reason for the global varying prevalence 
is still unknown. However, evidences exist that MS occurs in genetically high-risk individuals 
exposed to an environmental agent. 
A role for a genetic factor in disease susceptibility is supported by the familiar recurrence risk 
of MS that varied depending on the relatedness to the patient. First-degree relatives of MS 
patients have an approximately 15-25 fold higher risk (recurrence risk of 3-5%) to develop 
MS compared to the general population (lifetime prevalence 0.2%). In twin studies it was 
shown that there is a higher concordance rate in monozygotic twins (about 20%) in 
comparison to dizygotic twins (about 5%) (Dyment et al., 2004).  
Furthermore, gene variations have been linked with an increased risk to develop MS. The 
MHC class II alleles (MHC, major histocompatibility complex, in vertebrates this system is 
named HLA, human leukocyte antigen) DR15 and DQ6 with the following genotypes 
DRB1*1501, DRB5*0101, DQA1*0102, and DQB2*0602 were associated with MS 
especially in Northern Europe. In addition, gene variations in interleukin-2 and interleukin-7 
receptor α chains were linked to an increased susceptibility (Compston and Coles, 2008). 
The variable global disease distribution of MS with increasing prevalences to the north and 
south in both hemispheres from the equator suggested an environmental factor contributing to 
disease manifestation. Moreover, children migrating from high-risk to low-risk regions 
adopted the decreased risk of developing MS. Reversed migration in childhood is associated 
with an increased risk (Compston and Coles, 2008). 
In addition, clinical infections increased the risk of relapses in MS. Exacerbations that 
occurred during the period of a systemic infection led more frequently to sustained 
neurological deficits (Andersen et al., 1993; Buljevac et al., 2002; Sibley et al., 1985). Among 
putative infectious agents, Epstein-Barr (EBV) virus infection was strongly associated with 
MS (Ascherio and Munger, 2007a; Haahr and Hollsberg, 2006). It was suggested that EBV 
infection manifested as infectious mononucleosis in young adulthood is a risk factor for 
developing MS (Thacker et al., 2006). EBV interference with MS risk might involve 
mechanisms of molecular mimicry between viral and myelin components (Lang et al., 2002). 
In autopsy brain tissue of MS patients with different disease courses EBV-infected B 




WM lesions. MS cases with a secondary progressive disease course even exhibited ectopic B 
cell follicles in the meninges suggested to represent main sites of EBV persistence (Serafini et 
al., 2007). 
In addition to putative infectious agents, environmental factors like cigarette smoking, low 
sunlight, deficiency in vitamin D, diet, geomagnetism, air pollutants, radioactive rocks, and 
toxins have been suggested to trigger the development of MS (Ascherio and Munger, 2007b; 
Compston and Coles, 2008; Hernan et al., 2005; Mikaeloff et al., 2007). 
The female predominance of about 2:1 suggests hormones as nongenetic factor contributing 
to MS risk. This assumption was supported by the fact that the rate of relapses decreased 
especially during the third trimester of pregnancy but was increased immediately after birth 
(Confavreux et al., 1998). 
 
1.1.2 Diagnosis and clinical presentation 
The clinical course and response to immunomodulatory therapies of individual MS patients is 
very heterogenous. Clinical manifestation depends on the affected CNS region and most 
patients show visual, sensory, motor, and autonomic deficits. The expectancy of life is only 
slightly reduced. Fatality of MS cases is attributable to about 
2
/3 of patients and to the higher 
risk and complications of infections in progressive diseased individuals. A fulminant and fatal 
clinical disease course, in which MS patients die within month after disease onset, is rare 
(Marburg’s variant of MS). Impairment in social and work life are side-effects besides 
depression and suicide that remain a great risk among patients (Compston and Coles, 2008; 
Noseworthy et al., 2000). 
1.1.2.1 Diagnosis 
Guidelines for diagnostic criteria for MS have been established and revised (McDonald et al., 
2001; Polman et al., 2011; Polman et al., 2005). The basic concept in MS diagnosis is 
dissemination of lesions in space and time. Clinical, imaging, laboratory and physiologic 
evidences can contribute to diagnosis such as periods of neurologic dysfunctions, lesions 
detected in magnetic resonance imaging (MRI), disease progression, positive oligoclonal 
bands in cerebrospinal fluid (CSF) showing increased intrathecal synthesis of 
immunoglobulins of restricted specificity and prolonged latency of evoked potentials 





Neurologic disability in MS patients can be assessed by the Kurtzke Expanded Disability 
Status Scale (EDSS) (Kurtzke, 1983), a rating system with 10 steps from 0 (normal) to 10 
(death due to MS). 
1.1.2.2 Clinical disease courses in MS 
At disease onset about 80% of patients are affected by a relapsing-remitting disease course 
(RRMS) characterized by periodic episodes of neurologic deficits (relapses) followed by 
complete or partial recovery of the symptoms (remission). In about 10% of cases relapses are 
absent for more than 20 years and MS is considered to be benign. RRMS typically affects 
young adults in the second and third decade of life and shows a female to male predominance 
of ~2:1 (Noseworthy et al., 2000). In average ten years after disease onset ~50% of patients 
who suffered from RRMS enter a disease phase with a steady worsening of clinical 
symptoms, fewer relapses and incomplete recovery, called secondary progressive MS (SPMS) 
(Siffrin et al., 2010). About 20% of MS patients manifested a primary progressive disease 
course (PPMS) that is characterized by a gradually progressive deterioration of clinical 
symptoms from disease onset and a similar incidence between men and women (Noseworthy 
et al., 2000). 
Regardless of an initial relapsing-remitting or progressive disease course, the age at time of 
irreversible disability is about 40 years (Confavreux and Vukusic, 2006). In addition, if a 
clinical threshold of irreversible disability is passed, the following progression of impairments 
is neither affected by relapses before nor during this phase (Confavreux et al., 2003; 
Confavreux et al., 2000). 
1.1.2.3 Clinical correlates of cortical lesions 
MS was typically considered as a white matter (WM) disease but it has become increasingly 
obvious that the grey matter (GM) is frequently and extensively involved. Lesions in the GM 
may contribute to the so-called clinico-radiological paradox indicating that the WM pathology 
cannot explain the complete spectrum of clinical deficits (Barkhof, 2002). As an example, 
cognitive symptoms and epileptic seizures might be better explained by GM than WM 
pathology. Cognitive deficits are a common feature in MS affecting 40-65% of patients. 
These symptoms can affect patients with a RR disease course but is more severe in the 
progressive forms whereas it seems to be more pronounced in SPMS than PPMS (Amato et 
al., 2006; Chiaravalloti and DeLuca, 2008; Rinaldi et al., 2010). Imaging studies associated 




al., 2009; Roosendaal et al., 2009). Additional factors affecting cognitive performance are 
depression and fatigue that are also common symptoms in many patients with MS 
(Chiaravalloti and DeLuca, 2008; Feinstein, 2011). Furthermore, MS is linked to an increased 
risk of epilepsy than the general population (Catenoix et al., 2011; Spatt et al., 2001). It was 
shown that the accumulation of cortical lesions is higher in epileptic versus non-epileptic 
RRMS patients and that they exhibit a more severe cortical atrophy, more pronounced 
cognitive impairment and higher physical disability (Calabrese et al., 2008; Calabrese et al., 
2012b). An association of physical disability and the accumulation of cortical lesions has been 
confirmed in further MRI acquisition studies (Calabrese et al., 2012c; Calabrese et al., 
2010b). Interestingly, cortical lesions have even been detected in some patients a long time 
before MRI showed inflammatory lesions in the WM, which suggests that cortical 
demyelination could represent the initial pathological event in MS (Calabrese and Gallo, 
2009; Popescu et al., 2011). 
Treatment studies in RRMS patients showed an effect of disease-modifying drugs on cortical 
pathology in MRI over two years as assessed by a reduced accumulation of new cortical 
lesions and reduced progression of cortical atrophy compared to untreated patients (Calabrese 
et al., 2012a; Rinaldi et al., 2012). 
 
1.2 Myelin and myelin proteins 
Myelin or the myelin-forming oligodendrocytes are generally believed to be attacked by an 
autoimme response in MS leading to demyelination. Myelin is predominantly present in the 
WM of CNS tissue and gives these structures macroscopically the white appearance. 
However, myelin is also a component of the GM, albeit to a lesser extent, and ensheathes 
many axons originating from or terminating on cortical neurons. 
Myelin consists of 75% lipids and 25% proteins. The multilamellar myelin sheath is build by 
lipid-rich plasma membrane extensions of oligodendrocytes in the CNS, which spirally 
surround axons and thereby forming myelinated axon segments called internodes. Internodes 
are periodically interrupted by the so-called nodes of Ranvier resulting in short uncovered 
axon segments enabling saltatory nerve conduction. Thus, myelin functions as an electrical 
insulator and provides fast and energy-efficient impulse propagation over long distances. The 
loss of myelin was associated with a conduction block and increased vulnerability to axons 





In the most used animal model of MS research, experimental autoimmune encephalomyelitis 
(EAE), many myelin proteins like proteolipid protein (PLP), myelin basic protein (MBP), and 
myelin oligodendrocyte glycoprotein (MOG) have been shown to induce MS-like pathology 
and disease (Iglesias et al., 2001). 
1.2.1 Proteolipid protein (PLP) 
PLP is the major integral membrane protein of myelin in the CNS that account for ~50% of 
the CNS myelin protein mass. Two PLP forms are expressed, the full-length PLP (~30 kDa) 
and a shorter isoform, the splice variant DM20 (~20 kDa). Both proteins are primarily 
expressed in the CNS. DM20 can also be detected in the thymus, in which full-length PLP is 
only hardly detectable. Central tolerance to most epitopes to full-length PLP could be 
mediated by the higher expression of thymic DM20 (Goverman, 2011; Seamons et al., 2003). 
1.2.2 Myelin basic protein (MBP) 
MBP was the initial antigen with which CNS autoimmune diseases were elicited. MBP is a 
component of the central and peripheral myelin. In the CNS myelin MBP is the second most 
abundant protein (30-40% weight of membrane protein) whereas in the peripheral myelin it is 
less strongly expressed (5-15%). The MBP gene locus encodes two protein families, classic-
MBPs (~21.5 kDa) and golli-MBPs. Classic-MBP proteins are components of the myelin 
sheath in central and peripheral nervous system. Golli-MBP isoforms are expressed in the 
nervous system, thymus, peripheral lymphoid tissues. Central tolerance to epitopes from 
classic MBP could be mediated by the thymic expression of golli-MBP (Goverman, 2011; 
Seamons et al., 2003). 
1.2.3 Myelin oligodendrocyte glycoprotein (MOG) 
MOG is a ~28 kDa glycoprotein and highly conserved between species. MOG is 
quantitatively a minor component of myelin with 0.05-0.1% of the total myelin protein and is 
expressed on the outermost surface of the myelin sheath containing a single immunoglobulin-
like domain exposed to the extracellular environment (Johns and Bernard, 1999). MOG is 
primarily expressed in the CNS but MOG transcripts have been detected in mouse and human 
thymus (Derbinski et al., 2001; Pagany et al., 2003). 
 
1.3 Immunology of MS 
MS is considered as an autoimmune, CD4
+
 T cell-mediated disease of the CNS. In this current 




the formation of inflammatory demyelinated lesions, which lead to the manifestation of MS. 
A role for an autoreactive T cell response was supported by the findings that myelin-specific 
T cells have been isolated from MS patients although they also have been shown to exist in 
healthy individuals (Burns et al., 1983; Olsson et al., 1990; Pette et al., 1990; Richert et al., 
1983) and naïve animals (Anderson et al., 2000; Schluesener and Wekerle, 1985). 
Furthermore, in the widely used EAE model, MS-like diseases can be induced by active 
immunization with myelin antigens inducing a CD4
+
 T cell response or by adoptive transfer 
of activated myelin-specific CD4
+
 T cells in naïve recipients (Gold et al., 2006). Additionally, 
spontaneous EAE has been observed in mice expressing a transgenic myelin-specific T cell 
receptor (TCR) (Goverman et al., 1993; Pollinger et al., 2009; Waldner et al., 2000). Insights 
into disease pathomechanisms in MS were gained mostly from animal models and primarily 
from studies on EAE. 
1.3.1 Concept of autoimmune T cell responses 
The initiation of CNS inflammation required the presence of autoreactive CNS-specific T 
cells in the peripheral circulation that escaped central and peripheral tolerance mechanisms. 
Central tolerance in thymus can be escaped by autoreactive thymocytes with low avidity to 
the cognate antigen presented by antigen-presenting cells (APCs) or may be circumvented due 
to the limited number of thymic APCs presenting the self-antigen. In the periphery self-
tolerance might be maintained by regulatory T cells (Tregs) (Goverman, 2011). 
Before migration into the CNS peripheral myelin-specific T cells have to be activated. 
According to this, myelin epitopes have to be presented by APCs in the context of MHC class 
II (e.g. dendritic cells) but these conditions are still not understood (Goverman, 2009). 
Alternative mechanisms for autoreactive T cell activation could be molecular mimicry 
(Fujinami and Oldstone, 1985), a mechanism in which pathogens and self-antigens share 
cross-reactive epitopes, or bystander activation (Deshpande et al., 2001), a mechanism in 
which an unrelated infection might lead to the activation of pre-existing autoraggressive T 
cells (McCoy et al., 2006). Among other investigations, two important EAE studies 
performed by Reboldi et al., 2009 and Bartholomaus et al., 2009 shed light on the beginning 
of CNS inflammation (Ransohoff, 2009). Peripheral activated effector T cells migrate to and 
enter the still uninflamed CNS in a first wave by crossing the blood-cerebrospinal fluid (CSF) 
barrier in the choroid plexus in a C-C chemokine-receptor 6 (CCR6)-dependent manner and 
enter the subarachnoid space. Then, a second wave of T cells enter the CNS by crossing 




manner (Reboldi et al., 2009). In the first wave, T cell reactivation in the subarachnoid space 
has been shown to occur by interaction of T cells with MHC class II APCs (Kivisakk et al., 
2009), which lead to the activation of subpially and then distally microglial cells and blood 
vessels (Goverman, 2009). During the second wave of T cell entry, activated T cells arrested 
at and scanned activated blood vessels, crawled preferentially against the blood flow, crossed 
the blood vessel into the subarachnoid space and continued their scan. Encountering their 
specific antigen led to production of proinflammatory cytokines and CNS inflammation 
(Bartholomaus et al., 2009). Furthermore, these events led to activation/recruitment of 
macrophages/microglia and tissue damage such as demyelination and neurodegeneration. 
Activated macrophages/microglia might be the responsible cells for axonal damage because 
their number correlates with disease severity and they can secret harmful soluble factors 
(Gold et al., 2006). 
1.3.2 Role of CD4+ T cell effector subsets 
The differentiation of naïve CD4
+
 T cells into effector T cells with a distinct phenotype is 
induced by stimulation with cognate antigen presented on MHC class II molecules on 
professional APCs in the presence of co-stimulatory signals and a distinct cytokine milieux. 
Several CD4
+
 lineages such as T helper (Th) cells, subdivieded in type 1 (Th1), type 2 (Th2), 
type 17 (Th17), regulatory T cells (Tregs) and follicular helper T cells (Tfh) have been 
described. Tfh cells mediate B cell help for antibody production in germinal centers. Tregs 
derived from positively selected thymic CD4
+
 T cells with higher affinity to self-antigens than 
normal and are thought to suppress autoimmunity. The first classified Th cells were Th1 and 
Th2 cells. Th1 differentiation required interleukin (IL)-12 and the main effector cytokine is 
IFN-γ whereas Th2 cells differentiate in the presence of and secrete IL-4. Later, additional 
subsets were identified such as the IL-17, IL-21, and IL22-secreting Th17 cells that are 
stimulated by transforming growth factor (TGF)-β and IL-6 (Fletcher et al., 2010; Petermann 
and Korn, 2011; Zhu et al., 2010).  
IFN-γ-producing Th1 effector cells have been originally considered as the major pathogenic T 
cell in EAE and MS. The Th1 disease hypothesis was concluded from studies performed in 
IL-12p40 deficient mice that were resistant to EAE (Gran et al., 2002), adoptive transfer 
experiments in which myelin-specific Th1 cells induced EAE (Baron et al., 1993), 
observations that IFN-γ treatment exacerbated disease in MS (Panitch et al., 1987) and 
detection of IFN-γ in active MS lesions (Traugott and Lebon, 1988). However, this concept 




(IFN-γ deficient mice, IFN-γ receptor deficient mice and IL-12p35 deficient mice) were 
highly susceptible to EAE (Becher et al., 2002; Ferber et al., 1996; Gran et al., 2002; 
Willenborg et al., 1996). IL-12 is composed of the subunits p35 and p40. But p40 forms with 
the subunit p19 another cytokine IL-23 (Oppmann et al., 2000). IL-23 drives the 
differentiation of effector Th17 cells and it was shown, that adoptively transferred Th17 cells 
can induce EAE (Langrish et al., 2005). Both, IL-12 and IL-23 polarized Th1 and Th17 cells 
were pathogenic and induced similar EAE disease courses in mice but showed different 
expression patterns of CNS chemokines, composition and localization of infiltrating cells and 
responsiveness to immunomodulatory treatments (Kroenke et al., 2008). A relevant role for 
Th17 cells in MS was suggested by several observations. Th17 cells have been detected in 
CSF of patients with RRMS and interestingly, frequencies of Th17 cells were increased 
during relapses compared to patients in remission (Brucklacher-Waldert et al., 2009). 
Furthermore, IL-17 positive cells were detected in MS brain (Kebir et al., 2007; Tzartos et al., 
2008) and in vitro experiments showed that Th17 lymphocytes crossed more efficiently the 
BBB compared to Th1 cells (Kebir et al., 2007). 
1.3.3 Role of CD8+ T cells 
A putative involvement of CD8
+
 T cells in MS arose in gene association studies in HLA class 
I regions, which suggested a predisposition by the HLA-A3 allele (HLA-A*0301) and 
protection by the HLA-A2 allele (HLA-A*0201) (Friese and Fugger, 2009). In addition, 
histological studies showed a predominance of CD8
+
 T cells compared to CD4
+
 T cells and a 
clonal expansion of these CD8
+
 T cells in the MS lesions (Babbe et al., 2000; Frischer et al., 
2009). The recent described cortical GM lesions in early-stage MS patients also showed CD8
+
 
T cell infiltrates (Lucchinetti et al., 2011). Furthermore, the extent of axonal damage was 
correlated with the number of CD8
+
 T cells in MS lesions (Bitsch et al., 2000; Kuhlmann et 
al., 2002) and in vitro experiments showed that neurites can be damaged by cytotoxic CD8
+
 T 
cells (Medana et al., 2001). Due to the deficiency of CD8
+
 T cell-driven EAE models, only 
few studies could assess the role of these effector cells (Willing and Friese, 2012) that might 
exert pathogenic (Huseby et al., 2001) and regulatory functions (York et al., 2010). 
1.3.4 Role of antibodies and B cells 
MS research primarily focused on the role of T cells, however, the involvement of B cells and 
antibodies also attracted investigators in the recent years. Not only the presence of oligoclonal 
bands in CSF of MS patients (Kabat et al., 1942), which are important paraclinical diagnostic 




immunoglobulins (Ig) and components of the complement in many MS lesions (designated as 
pattern II) (Lucchinetti et al., 2000) and responsiveness of patients exhibiting such lesion 
pattern II to plasma exchange (Keegan et al., 2005) confirmed an involvement of humoral 
factors like antibodies in MS. The myelin surface protein MOG was characterized by the 
particular ability to induce a demyelinating autoantibody response in parallel to an 
encephalitognic T cell response (Gold et al., 2006). MOG-induced EAE in rats shared 
important aspects of the pathology in MS (Adelmann et al., 1995; Johns et al., 1995) and a 
direct pathogenic role for a MOG-specific monoclonal antibody was shown by the 
augmentation of demyelination in vivo in rat EAE models (Lassmann et al., 1988; Linington 
et al., 1988; Schluesener et al., 1987). Even serum obtained from MS patients with high anti-
MOG autoantibody titers enhanced demyelination and axonal damage in rats with EAE (Zhou 
et al., 2006). Moreover, MOG autoantibodies have been detected in WM lesions in EAE and 
MS and were associated with myelin damage (Genain et al., 1999; Raine et al., 1999). 
Additionally, an autoantibody response against the potassium channel KIR4.1 expressed on 
glial cells was shown in a proportion of MS patients (Srivastava et al., 2012). However, the 
epitope(s) recognized by specific pathogenic antibodies is still unknown (Iglesias et al., 2001). 
In contrast to pathogenic IgG antibodies showed IgM antibodies beneficial effects and have 
been shown to promote remyelination in animal models of MS (Bieber et al., 2002; Miller et 
al., 1994; Warrington et al., 2007).  
B cells and plasma cells are involved in antibody production and secretion. In recent studies 
an involvement of B cells in MS was suggested as depletion of circulating B cell populations 
by administration of rituximab, a chimeric monoclonal antibody specific for CD20
+
 B cell 
(not plasma cells), decreased brain lesions and relapses in RRMS (Bar-Or et al., 2008; Hauser 
et al., 2008). In contrast, atacicept, a human recombinant fusion protein containing binding 
sites for two important cytokine regulators of B cell maturation, function and survival, that 
selective impair mature B cells and antibody-secreting plasma cells was shown to increase 
disease activity in MS (Hartung and Kieseier, 2010). B cells might contribute to disease 
independent of antibodies. In EAE it was shown that the time-dependant depletion of B cells 
influenced EAE outcome (Matsushita et al., 2008) and interleukin 6 secreting B cells might 





1.4 Pathology of MS 
Inflammation, de- and remyelination, neurodegeneration and glial scar formation are 
pathological characteristics occurring in the brain and spinal cord of MS patients. Tissue 
damage can occur in a focal or global diffuse manner and is disease-stage dependent. Both, 
WM and GM areas can be affected, whereas the GM in the cerebral cortex is extensively 
involved (Kidd et al., 1999; Lassmann et al., 2007; Lassmann et al., 2012; Peterson et al., 
2001). 
1.4.1 Immunopathology 
Primarily active lesions, which are most frequent in patients with acute disease or RRMS, are 
accompanied by inflammatory infiltrates composed of T cells, B cells, plasma cells and 
activated macrophages/microglia in which CD8
+
 T cells outnumber CD4
+
 T cells (Babbe et 
al., 2000; Friese and Fugger, 2009; Frischer et al., 2009; Lucchinetti et al., 2000). In early 
active stage demyelinated lesions in the WM, identified by myelin destruction and 
macrophages/activated microglia containing intracytoplasmic myelin products, four different 
patterns have been described. Pattern I and II lesions described early active demyelination 
with a T cell- and macrophage-dominated inflammation. Pattern II lesions showed additional 
deposition of immunoglobulins (mainly IgG) and complement C9neo. The other two patterns 
III and IV were thought to arise through a primary oligodendrocyte dystrophy. Lesion patterns 
were homogeneous within multiple early active lesions from the same patient but 
heterogeneous between different patients (Lucchinetti et al., 2000). Inflammation in WM 
lesions might be associated with damage to the BBB as shown by gadolinium-enhanced 
lesions in MRI (Miller et al., 1988). Slowly expanding lesions, inactive and remyelinated 
lesions showed less inflammation (Lassmann et al., 2012). 
Cortical demyelinated lesions in early MS disease-stage have been described very recently 
and were identified as inflammatory and strongly associated with meningeal inflammation. 




 T cells as well as 
but to a lesser extent B cells (Lucchinetti et al., 2011; Popescu et al., 2011). As the patient 
presented by Popescu et al., in 2011 showed an inflammatory cortical lesion linked to 
gadolinium enhancement in MRI it was suggested that inflammation induced damage of the 
BBB in cortical lesions. 
Chronic cortical lesions in late-stage disease were found to be less inflammatory than early 
cortical lesions (Bo et al., 2003a; Peterson et al., 2001) probably due to long intervals between 




identified in progressive MS (Magliozzi et al., 2007; Serafini et al., 2004) that were associated 
with subpial demyelination (Kutzelnigg et al., 2005). Moreover, the severity of meningeal 
inflammation correlated with GM demyelination and neurite loss (Choi et al., 2012; Howell et 
al., 2011). In immunohistological studies it was suggested that the BBB integrity is relatively 
preserved in intracortical GM lesions due to the lack of markers for BBB disruption or 
astrogliosis (van Horssen et al., 2007). Furthermore, in cortical GM lesions some complement 
deposition was found (Brink et al., 2005; Schwab and McGeer, 2002) probably sheding light 
on a possible pathomechanism mediated by humoral factors. 
1.4.2 Demyelination 
Plaques of focal demyelination are characteristic hallmarks of all MS disease stages and they 
can be classified depending on the activity into classic active lesions, slowly expanding 
lesions, inactive lesions or remyelinated shadow plaques by the level of inflammatory 
activity, axon loss or remyelination status (Lassmann et al., 2012). 
WM lesions showed variable densities of oligodendrocytes at all stages of demyelinating 
activity between nearly complete loss and numbers exceeding densities in the periplaque WM 
(Lucchinetti et al., 1999). 
Although the early description of cortical demyelination by Charcot in the late 18
th
 century 
(Popescu and Lucchinetti, 2012) and other neuropathologists later on (Brownell and Hughes, 
1962; Dinkler, 1904; Lumsden, 1970; Sander, 1898; Taylor, 1892) remained cortical lesions 
understudied over a long time period until improved immunohistological staining techniques 
led to a histopathological reinvestigation of GM pathology (Bo et al., 2003a; Bo et al., 2003b; 
Giaccone et al., 2012; Kidd et al., 1999; Peterson et al., 2001; Vercellino et al., 2005). 
Cortical demyelination was thought to occur in part independently to pathologic WM changes 
(Bo et al., 2007; Giaccone et al., 2012; Kutzelnigg et al., 2005) and may represent an early or 
initial target of MS (Calabrese and Gallo, 2009; Popescu et al., 2011).  
Currently, cortical lesions are classified into four types depending on their localization (Bo, 
2009; Calabrese et al., 2010a; Popescu and Lucchinetti, 2012) based on the system used in 
Kidd et al., 1999, simplified in Peterson et al., 2001 and modified by Bo et al., 2003b. 
Accordingly, leukocortical lesions extending through both WM and GM were assigned to 
lesion type I. Purely intracortical lesions that neither extend to the pial surface nor to the 
subcortical WM were defined as lesion type II. Cortical lesions of type III classified subpial 




the cortex without affecting the subcortical WM were assigned to lesion type IV. Type III and 
IV lesions were both classified as subpial lesions. 
Very recently, extensive and well-demarcated cortical demyelinating lesions have been 
described in early disease-stage MS patients with the most common lesion type located 
leukocortical followed by subpial and intracortical lesions. Lesions were primarily classified 
as active and contained often foamy, myelin-laden macrophages indicative for ongoing 
demyelination. Additionally, in a subset of lesions a reduction of oligodendrocyte density was 
observed in comparison to nearby myelinated cortex (Lucchinetti et al., 2011; Popescu et al., 
2011). 
Although already present in RRMS and acute MS, cortical demyelination was most prominent 
and extensive in patients with a progressive disease stage (Kutzelnigg et al., 2005) and the 
most common lesion type was subpial (Albert et al., 2007; Bo et al., 2003b; Kutzelnigg et al., 
2005; Peterson et al., 2001; Vercellino et al., 2005). Chronic cortical lesions also showed 
well-demarcated area of demyelination and oligodendrocyte/glial cell loss (Albert et al., 2007; 
Bo et al., 2003a; Bo et al., 2003b; Peterson et al., 2001; Wegner et al., 2006). 
The degree of cortical demyelination varied regionally with the most affected brain areas in 
the cingulate gyrus (17-44%) followed by the temporal and frontal cortices (17-28%). Less 
damage occurs in the paracentral lobule (11.5%), occipital lobe (8%) and primary motor 
cortex (3.5%) (Bo, 2009). 
1.4.3 Remyelination 
Remyelination is a regenerative repair mechanism in demyelinated plaques that restores the 
lost myelin sheath (Franklin and Ffrench-Constant, 2008). It was shown that remyelination 
prevented axonal loss after demyelination (Irvine and Blakemore, 2008) and played a role in 
functional recovery (Liebetanz and Merkler, 2006; Manrique-Hoyos et al., 2012; Merkler et 
al., 2009). Histologically, variable degree of remyelination can be noted, which was most 
extensive in the so-called shadow plaques. Characteristic for remyelinated plaques was the 
reduced myelin density in comparison to the surrounding normal appearing brain matter due 
to a thinner myelin sheath thickness (Bruck et al., 2003). Extensive remyelination can be 
observed in the WM in RRMS and MS patients in progressive disease stages (Patani et al., 
2007; Patrikios et al., 2006). However, remyelination is often incomplete or absent although 
oligodendrocyte precursor cells (OPCs) have been shown to be present in chronic lesions but 
it seemed that they failed to proliferate and differentiate (Wolswijk, 1998). Differentiation of 




Remyelinating capacity has also been observed in cortical GM lesions and was even more 
extensive in cortical lesions in comparison to WM lesions (Albert et al., 2007). Remyelinated 
plaques contained an increased number of oligodendroglia at the lesion border compared to 
the demyelinated center of lesions or control cortex (Albert et al., 2007). Furthermore, 
remyelination has also been observed in the cerebral cortex of animal models after a 
demyelinating event (Merkler et al., 2006b; Merkler et al., 2009; Skripuletz et al., 2008). 
1.4.4 Neurodegeneration and atrophy 
Axonal damage, transection and loss (Ferguson et al., 1997; Lovas et al., 2000; Trapp et al., 
1998), progressive brain atrophy (Fisher et al., 2002; Rudick et al., 1999), decrease of the 
neuronal marker N-acetyl aspartate (NAA) (Bjartmar et al., 2000) and neuronal loss 
(Papadopoulos et al., 2009; Wegner et al., 2006) have been associated with MS (Trapp and 
Nave, 2008). Progressive axon degeneration is considered as the main cause of gradually 
worsening of irreversible neurologic deficits in MS (Trapp and Nave, 2008). In MS lesions, 
acute axonal damage is mostly prominent in early disease stages, correlated with 
inflammation and decreased over time (Kuhlmann et al., 2002). Diffuse axonal injury was 
also detected in normal appearing WM (NAWM) but more pronounced in progressive disease 
compared to acute or RRMS (Kutzelnigg et al., 2005). Demyelination is not a prerequisite for 
axon damage, which can be reversible (Nikic et al., 2011). Mechanims leading to axon 
damage in acute lesions may include vulnerability of demyelinated axons to the inflammatory 
environment, glutamate-mediated excitotoxicity or cytotoxic CD8
+
 T cells (Trapp and Nave, 
2008). In addition to neuronal pathology in the WM the neuronal compartment in the GM was 
also affected. 
In early-stage MS, it was shown that several cortical demyelinated lesions showed neuritic 
swellings indicative for acute damage. However, the majority of lesions showed relative 
preservation of neurits. In rare cases, focal neuritic loss was observed (Lucchinetti et al., 
2011).  
Chronic cortical lesions showed neuronal damage as indicated by apoptosis, a mild to 
moderate neuronal loss, smaller neuronal sizes and transected axons and dendrites in the 
demyelinated cortex (Choi et al., 2012; Magliozzi et al., 2010; Peterson et al., 2001; 
Vercellino et al., 2005; Wegner et al., 2006). Neuronal loss was not restricted to lesions as it 
was also observed in normal appearing GM (NAGM) (Choi et al., 2012; Magliozzi et al., 
2010). Loss and injury of thalamic and cortical neurons by measuring NAA levels has also 




addition, synaptic loss was detected in leukocortical lesions (Wegner et al., 2006). However, 
another study found no reduction in synaptic density (Vercellino et al., 2005). 
GM atrophy was also shown to be a pathologic hallmark of MS. GM atrophy can occur early 
in the disease, increased with disease stage and was related to disease progression (De Stefano 
et al., 2003; Fisher et al., 2008; Rudick et al., 2009). As additional parameter thinning of 
cortical thickness was detected in MS patients in MRI studies (Chen et al., 2004; Sailer et al., 
2003) and in a histological study (Wegner et al., 2006). 
Permanent deficits in MS may occur when axonal loss exceeds a threshold that CNS 
mechanisms cannot compensate for (Bjartmar et al., 2003; Dutta and Trapp, 2007). 
Compensatory processes may include axonal remodeling leading to restoration of damaged 
axonal connections as it was shown in MS-like lesions in rats (Kerschensteiner et al., 2004a). 
 
1.5 Animal models of MS 
Animal models have been very useful tools to investigate putative pathomechanisms and test 
therapeutic approaches in inflammatory, demyelinating diseases like MS. Depending on the 
needs, immune-mediated, toxic, viral and genetic models have been established (Ransohoff, 
2012). 
1.5.1 Experimental autoimmune encephalomyelitis (EAE) 
The most used animal model in MS research is EAE, which is an immune-mediated disease 
leading to inflammatory demyelinated lesion in the CNS. The view, that MS is a T cell-
mediated autoimmune disease and most of our current knowledge concerning CNS 
inflammation derived from studies on EAE. 
EAE was first described by Thomas Rivers in the early 1930s (Rivers et al., 1933). Rivers and 
colleagues repeatedly injected intramuscularly rabbit brain homogenates in rhesus monkeys 
and observed in two out of eight treated animals clinical signs (ataxia, weakness, paresis). 
Tissue sections revealed inflammation and demyelination in the CNS. From the date EAE was 
elicited in various species including marmoset monkeys, guinea pigs, rats and mice by either 
immunization with CNS tissue or myelin-derived antigens, usually emulsified in complete 
Freund’s adjuvant (CFA) or adoptive transfer of activated autoaggressive T cells, and led to 
the establishment of well-characterized animal models reflecting specific features of the 
immunopathology in MS. CFA is a mineral oil-based solution containing components of heat-
inactivated mycobacteria tuberculosis that stimulated induction of EAE (Gold et al., 2006). 




subcutaneous active immunization with MOG-peptide (amino acids 35-55) emulsified in CFA 
and additional injection of pertussis toxin to augment disease induction. This ‘conventional’ 
EAE was reproducible and benefits from the diversity of transgenic and knockout mice 
available on a C57BL/6 background. Unfortunately this EAE displayed only a chronic 
monophasic disease course (without recurring disease bouts), elicit primarily a CD4
+
 T cell 
response and predominantly affected the spinal cord leading to the classic symptoms of 
ascending paralysis (Ransohoff, 2012). EAE can also be induced by immunization with 
MOG1-125 (amino acids 1-125) in CFA in C57BL/6 leading to a similar chronic-progressive 
disease course. Another standard EAE mouse model eliciting a relapsing-remitting disease 
course was induced in SJL mice by immunization with PLP-peptide (amino acids 139-151) 
emulsified in CFA (Gold et al., 2006). BiozziABH mice represent another mouse strain also 
highly susceptible to EAE. These mice exhibited a chronic relapsing-remitting disease course 
upon immunization with homologous spinal cord homogenate, myelin containing full-length 
‘native’ MOG or myelin antigens such as MOG1-125 in adjuvant among other CNS antigens. 
Inflammation and demyelination are particular evident during the relapse/chronic disease 
phase (Amor et al., 1994; Amor et al., 2005; Baker et al., 1990; Smith et al., 2005). 
Additionally to active immunization schemes, EAE can be elicited by adoptively transferred 
activated myelin-specific T cells in different species (Ben-Nun et al., 1981; Zamvil et al., 
1985). 
1.5.2 Targeted EAE models 
In the above mentioned ‘conventional’ rodent EAE models, inflammation primarily targets 
the spinal cord leading to disseminated spinal lesions in space and time. An animal EAE 
model showing demyelinated inflammatory lesions randomly distributed in the cerebral 
cortex similar to those in MS has been described in marmoset monkeys (Merkler et al., 2006a; 
Pomeroy et al., 2008; Pomeroy et al., 2005). Later, ‘conventionally’ MOG1-125-immunized 
rats (LEW.1W and LEW.1AR1 rat strains) showed extensive cortical demyelination 
distributed in the forebrain (Storch et al., 2006). In active immunized mice (MOG35-55 in mice 
on a C57BL/6 background, PLP139-151 in SJL/J mice) cortical lesions were detected by a 
decreased or absent intensity of myelin staining (Girolamo et al., 2011; Mangiardi et al., 
2011; Rasmussen et al., 2007). Unfortunately, lesions that occur randomly in anatomical 
localization are difficult to study precisely. These limitations were overcome by the 
introduction of localized EAE models targeting a predetermined area. The first inflammatory 




proinflammatory cytokines in a predetermined spinal region led to local inflammation, focal 
demyelinated lesions and axonal damage in this area sharing similarities with MS lesions 
(Kerschensteiner et al., 2004b). In 2006, the targeted spinal cord EAE was transferred to the 
cerebral cortex as a model reflecting human GM pathology was still missing. Merkler and 
colleagues adjusted the protocol from the targeted spinal cord EAE (from Kerschensteiner et 
al., 2004b) and developed a focal EAE rat model for cortical demyelination reflecting key 
features of cortical MS lesions. They stereotactically injected a mixture of proinflammatory 
cytokines into the cortex and triggered local demyelinated lesions. These lesions showed 
cortical inflammation (T cells and activated macrophages/microglia) as early, transient and 
rapidly resolving phenomenon, deposition of complement C9, rapid remyelination, acute 
axonal damage but no apparent loss thereafter and sporadic irreversible neuronal damage 
(Merkler et al., 2006b). This model also shed light on an association between cortical 
demyelination and cortical function. By measuring the propagation velocity of a wave of 
depolarization of neurons and glia cells in GM (cortical spreading depression) it was shown 
that the velocity of this propagating wave inversely correlated with the myelin content 
(Merkler et al., 2009). Unfortunately, further mechanistic studies on cortical pathology were 
hampered by the lack of useful transgenic rat strains. 
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2 AIM OF THE STUDY 
The increasing association between inflammatory demyelinated lesions within the cerebral 
cortex and clinical impairments in MS patients demonstrated the urgent need for a suitable 
mouse model to study cortical pathology. The present project aimed to establish and 
characterize a mouse model that reflects key pathological features of cortical MS lesions. In 
order to facilitate studies on cortical pathology a targeted model was sought, in which lesions 
were induced in a predetermined cortical area in a defined time window by an inflammatory 
stimulus. MS patients in early disease-stages showed cortical lesions with demyelination and 
inflammation, therefore, the modeled cortical lesions should be accompanied by infiltrates 
composed of T cells and activated macrophages/microglia and loss of myelin. Furthermore, 
the next step of the project was to elucidate neuronal pathology as measured by axonal density 
and neuronal numbers since some extent of neuronal injury was detected in lesions of early 
MS patients but is most prominent in late-stage disease. Furthermore, a method allowing 
detailed studies on dendritic pathology in mice should be established. In addition, dendritic 
pathology was assessed in the cerebral cortex of chronic MS patients. 
Following specific aims were addressed in this doctoral thesis: 
1) Establishment of a targeted EAE mouse model showing cortical demyelinated lesions 
triggered by an inflammatory stimulus. 
2) Characterization of targeted cortical EAE with regard to the extent of demyelination, 
capacity for remyelination and inflammation (T cells, activated macrophages and 
microglia) and neuronal pathology (axonal and neuronal densities). 
3) Establishment of three-dimensional (3D) reconstruction and analysis of dendritic 
processes in the cerebral cortex of mice. 
4) Assessment of abnormalities in dendritic branch pattern and number of dendritic 
spines in cortical GM of progressive MS patients. 
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3 MATERIAL AND METHODS 
3.1 Material 
3.1.1 Reagents 
Reagent     Company   Catalog number 
Animal experimentation 
Aqua ad iniectabilia    BBraun   #353 5665 
Dulbecco’s Phosphate Buffered Saline 
(DPBS), 1x     Gibco    #14190-094 
Esconarkon     StreuliPharma AG  #55815002 
Freund’s Adjuvant Incomplete  Sigma-Aldrich  #F5506 
Isoflurane     Nicholas Piramal (I) Limited 
Ketasol-100 (Ketamine)   Graeub   #668.51 
Monastral Blue (Copper(II)phthalocyanine- 
tetrasulfonic acid tetrasodium salt)  Sigma-Aldrich  #274011 
Mouse VEGF (164aa)   MACS MiltenyiBiotec #130-094-087 
Mycobacterium Tuberculosis H37Ra Difco    #231141 
Paraformaldehyde (PFA)   AppliChem   #A3813 
Pertussis toxin    Sigma    #P2980 
Phenol red     Sigma-Aldrich  #32661 
Prequillan (Acepromazine)   Fatro    #56 719 
Recombinant Mouse TNF-α aa 80-235 R&D Systems   #410-MT/CF 
Recombinant Murine IFN-γ   PeproTech GmbH  #315-05 
Rompun 2% (Xylazine)   Bayer HealthCare  #35 464 
Sodium azide     Sigma-Aldrich  #S2002 
 
 Proteinbiochemistry 
Acetic acid (glacial) 100%   Merck    #1.00063.2500 
Acrylamide/Bis Solution 29:1, 40%  Bio-Rad   #161-0146 
Agar, granulated    Difco    #214530 
Ammonium Persulfate   Amersham   #171311-01 
β-Mercapthoethanol    PlusOne   #17131701 
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BSA Standard     Bio-Rad   #500-0206 
Bradford Protein Assay, 1x Dye Reagent Bio-Rad   #500-0205 
Bromophenol Blue    Bio-Rad   #161-0404 
Complete protease inhibitor cocktail tablets Roche    #04693116001 
Coomassie Brilliant Blue R 250  Sigma    #27816 
DNAse I     Roche    #04716728001 
DL-Dithiothreitol (DTT)   Sigma    #D9779 
EDTA      Fluka    #03680 
Glycerol for molecular biology, 99% Sigma    #G5516 
Glycine     Bio-Rad   #161-0718 
Imidazole     Sigma    #56748 
IPTG      Invitrogen   #15529-019 
Javel water 13/14%    Reactolab   #10200-150 
Kanamycin     Roth    #T832.1 
LDAO      Sigma    #40236 
Lysozyme     AppliChem   #A3711 
Protein Standard Dual Color   Bio-Rad   #161-0374 
SDS, 20% Solution    AppliChem   #A3942 
Sodiumacetate    Fluka    #71185 
Sodium chloride    Acros Organics  #207790050 
Sodium dihydrogen phosphate monohydrate Fluka    #71506 
Sodium phosphate dibasic dihydrate  Sigma-Aldrich  #30435 
Sodium phosphate dibasic heptahydrate Sigma-Aldrich  #S9390 
Talon Metal Affinity Resin   Clontech   #635503 
TEMED     Sigma    #T7024 
Tris (MW121g/mol)    Bio-Rad   #161-0719 
Tryptone     BD Bacto   #211705 
Urea      Sigma    #51456 
Yeast Extract     BD Bacto   #212750 
 
 DNA isolation and genotyping PCR 
Agarose     Promega   #V3125 
dATP      Fermentas   #R0141 
dCTP      Fermentas   #R0151 
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dGTP      Fermentas   #R0161 
dTTP      Fermentas   #R0171 
GeneRuler 100bp DNA Ladder  ThermoScientific  #SM0321 
Green GoTaq reaction buffer, 5x (M791A) Promega   #M3175 
GoTaq DNA Polymerase (M830B)  Promega   #M3175 
QuickExtract DNA Extraction Solution epicenter   #QE09050 
SybrSafe DNA gel stain   Invitrogen   #S33102 
Water Molecular biology grade  AppliChem   #A7398 
 
Primer   Sequence      Company 
GFP-geno Fwd  5’-AAG TTC ATC TGC ACC ACC G-3’  Microsynth 
GFP-geno Rev  5’-TCC TTG AAG AAG ATG GTG CG-3’  Microsynth 
GFP-intctrl Fwd 5’-CTA GGC CAC AGA ATT GAA AGA TCT-3’ Microsynth 
GFP-intctrl Rev 5’-GTA GGT GGA AAT TCT AGC ATC ATC C-3’  Microsynth 
 
 ELISA 
BSA (Albumin – Fraction V)  AppliChem   #A1391,0100 
FBS Superior     Biochrom AG   #S0615 
Sulfuric acid 95-97%, p.a.   Merck    #731 
TMB      Moss, Inc.   #TMBUS-1000 
Tween 20     Sigma-Aldrich  #P9416 
 
Histology and immunohistochemistry 
Acetone     Acros Organics  #176800025 
Alcohol absolutus 2% MEK (Ethanol) Brenntag   #13229-307 
Ammonium hydroxide, 32%   Merck    #1.05426 
Calcium carbonate    Merck    #5286707 
Citric acid monohydrate   Merck    #1.00244 
Chromium(III) potassium sulfate  
dodecahydrate     Sigma-Aldrich  #243361 
DAB chromogen + substrate buffer  Dako    #K3468/K5001 
Dako Real antibody diluent   Dako    #S2022 
Dako Real peroxidase blocking solution Dako    #S2023 
Dako wash buffer, 10x   Dako    #S3006 
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DAPI (Dilactate)    Invitrogen   #D3571 
Formalin (Formaldehyde solution min 37%) Merck    #1.04003.1000 
Fluoprep     bioMérieux   #75 521 
Gelatin from porcine skin   Fluka    #48722 
Isopentane (2-Methylbutane)   Merck    #106056 
MayersHemalaun    Merck    #1.09249.0500 
Mercury chloride    Merck    #4419 
Methanol     Acros Organics  #176840025 
Nitric acid, 65%    Merck    #100456 
Paraffin (Embedding System)  H-Plast   #95100.00 
Paraffin (Tissue Processor)   Brenntag   #12270-331 
Potassium chromate    Sigma-Aldrich  #216615 
Potassium dichromate   Sigma-Aldrich  #60188 
Silver nitrate     Roth    #9370.2 
Sodium carbonate    Sigma    #S2127 
Sodium dihydrogen phosphate monohydrate Fluka    #71506 
Sodium hydroxide    Fluka    #71690 
Sodium phosphate dibasic heptahydrate Sigma-Aldrich  #S9390 
Sodium thiosulfate pentahydrate  Merck    #106516 
Sucrose     Fluka    #84097 
Tissue-Tek O.C.T. compound  Sakura    #4583 
Triton X-100     Fluka    #93418 
UltraClear     J.T.Baker   #3905 
Ultrakitt (mounting medium)   J.T.Baker   #3921 
 
3.1.2 Antibodies 
Antigen  Isotype Clone  Company  Catalog number 
Primary antibodies for immunohistochemistry 
MBP   Rabbit IgG polyclonal Dako   #A0623 
Mac-3 (CD107b) RatIgG1 M3/84  BioLegend  #108501 
NeuN   Mouse IgG1 A60  Millipore  #MAB377 
CD3   Rat IgG1 CD3-12 AbD Serotec  #MCA1477  
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 Secondary antibodies for immunohistochemistry 
Alexa Fluor 555 Goat-anti-Rabbit IgG (H+L) Invitrogen  #A21429 
Fab Fragment Goat-anti-mouse IgG (H+L)  JacksonImmunoRes. #115-007-003 
Dako EnVision HRP labeled polymer anti-rabbit Dako   #K4003 
Dako EnVision HRP labeled polymer anti-mouse Dako   #K4001 
Polyclonal Rabbit Anti-Rat Immunoglobulins/Biotinylated Dako  #E0468 
Dako Real Streptavidin Peroxidase (HRP)  Dako    #K5001 
 
Antibody for ELISA 
Anti-Mouse IgG-Peroxidase Conjugate Sigma-Aldrich  #A8924 
 
 
3.1.3 Buffers and solutions 
Animal experimentation 
Monastral Blue,3% 
  Monastral Blue     0.03g 
  Sterile PBS      1ml 
 
Paraformaldehyde (PFA), 8%: 
  PFA       80g 
  10 M sodium hydroxide    ~ 5 drops 
  10x PBS      100ml 
  Distilled water     fill up to 1000ml 
  Adjust to pH = 7.3 and filter 
Store at -20°C  
 
PFA, 4%: 
  8% PFA      500ml 
  1x PBS      500ml    
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Phosphate buffered saline (PBS), 10x 
  Sodium phosphate dibasic dihydrate   12.8g 
  Sodium dihydrogen phosphate monohydrate 3.86g 
  Sodium chloride     85g 
  Distilled water     fill up to 1000ml 
 
PBS-sodium azide, 0.02% 
  10x PBS      10ml 
  Sodium azide      0.02g 




  APS       0.1g 
  Distilled water     1ml 
 
Coomassie destain solution 
  100% acetic acid (glacial)    10% 
  Methanol      10% 
  In distilled water 
 
Coomassie stain solution, 0.1% 
  Coomassie R250     1g 
  Methanol      400ml 
  Distilled water     500ml 
  100% acetic acid (glacial)    100ml 
 
Dialysis buffer, 1x 
  Sodium acetate      4.1g (10 mM) 
  Distilled water     fill up to 5l 
  100% acetic acid (glacial)    2.875ml 
  Adjust to pH = 3 
 
 




  Imidazol      3.404g 
  8 M urea      fill up to 50ml 
  Store at 4°C 
 
Imidazol, 40mM 
  1 M imidazol      2400µl 
  8 M urea       fill up to 60ml 
 
Imidazol, 5mM 
  1 M imidazol      175µl 
  8 M urea      fill up to 35ml 
 
IPTG, 1M 
  IPTG       1g 
  Aqua ad iniectabilia     4.2ml 
 
Kanamycin 
  Kanamycin      40mg  
  Aqua ad iniectabilia     1ml 
 
LB agar 
  Tryptone      10g 
  Yeast Extract      5g 
  Sodium chloride     10g 
  Agar       15g 
  Distilled water     fill up to 1l 
  Adjust to pH 7 
Treat by autoclave 









  Tryptone      10g 
  Yeast Extract      5g 
  Sodium chloride     10g 
  Distilled water     fill up to 1l 
  Adjust to pH 7.4 
Treat by autoclave 
40 mg/ml Kanamycin     1ml 
 
Sample loading buffer, 5x 
  Tris, pH = 6.8      0.25M 
  Glycerol      50% 
  SDS       5% 
  DTT       0.5M 
  Bromophenol Blue     0.02%  
  In distilled water 
 
SDS running buffer, 10x 
  Tris       250mM 
  Glycine      2.5M 
  SDS       1% 
  In distilled water 
 
Separation buffer, 2x 
  Tris, pH = 8.8      0.75M 
  SDS       0.2% 
  In distilled water 
 
Separation gel, 15% 
  2x separation buffer     5ml 
  40% Acrylamide/Bis Solution 29:1   3.75ml 
  Distilled water     1.25ml 
  TEMED      5µl 
  10% APS      50µl 




  8 M urea      10ml 
  β-Mercapthoethanol     14µl (20 mM) 
 
Sonication buffer 
  Sodiumchloride      17.53g (300 mM) 
  Sodiumphosphatedibasicheptahydrate   6.7g (25 mM) 
  Sodiumdihydrogenphosphatemonohydrate   3.45g (25 mM) 
 
Stacking buffer, 2x 
  Tris, pH = 6.8      0.25M 
  SDS       0.2% 
  In distilled water 
 
Stacking gel, 4% 
  Stacking buffer 2x     1ml 
  40% Acrylamide/Bis Solution 29:1   200µl 
  Distilled water     800µl 
  TEMED      5µl 
  10% APS      50µl 
 
TAE buffer, 1x 
  Tris       0.04M 
  Glacial acetic acid     0.04M 
  EDTA       0.002M 
  In distilled water 
 
TE buffer, 1x 
  Tris       10mM 
  EDTA       1mM 
  In distilled water 
  Adjust to pH = 7 
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Tris stock solution, 1M 
  Tris       121g 
  Distilled water     fill up to 1l 
Adjust to pH = 6.8 or pH = 8.8 
 
Urea, 8M 
  Urea       480.48g 
  Distilled water     fill up to 1l 
 
Wash buffer 
  LDAO       8.5ml 




Sulfuric acid, 2N 
  95-97% sulfuric acid     51.12ml 
  Distilled water     448.9ml 
 
Sulfuric acid, 1N 
  2N sulfuric acid     100ml 
  Distilled water     100ml 
 
PBS-T0.05% 
  1x PBS      1l 
  Tween 20      0.5ml 
 
PBS-T0.05%/10%FBS 
  1x PBS      10ml 
  Tween 20      0.005ml 








Citrate buffer, 10x (0.1M), pH = 6 
  Citric acid monohydrate    21g 
  Distilled water     fill up to 1l 
Adjust to pH = 6 
 
Citrate buffer, 1x (0.01M), pH = 6 
  Citrate buffer 10x     100ml 
  Distilled water     900ml 
 
Developer solution (Bielschowky’s silver staining) 
  Formalin      20ml 
  Distilled water     100ml 
  Citric acid monohydrate    0.5g 
  Nitric acid      2 drops 
 
Formalin, 10% 
  Formalin neutral     100ml 
  Distilled water     900ml 
 
Formalin neutral 
  Formalin      1l 
  Calcium carbonate     add until saturation 
Filter 
 
Formalin with salt 
  Formalin      1l 
  Sodiumdihydrogenphosphatemonohydrate  40g 
  Sodium phosphate dibasic heptahydrate  60g 
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Gelatin solution for coating slides (0.5%) 
Gelatin      0,25g 
Chromium (III) Potassium Sulfate Dodeca-H 0,05g 
Distilled water     fill up to 50ml 
 
Sorensen’s phosphate buffer, 0,4M 
  Sodium phosphate dibasic heptahydrate  87.92g 
  Sodium dihydrogen phosphate monohydrate 9.94g 
  Distilled water     fill up to 1l 
  Adjust to pH = 7.4 
 
3.1.4 Laboratory animals 
BiozziABH/RijHsd (reffered to as BiozziABH) inbred mice were purchased from Harlan 
Laboratories (Order code: 937). EGFP-M mice (B6.Cg-Tg(Thy1-EGFP)MJrs/J on a 
C57BL6/J background), in which EGFP is expressed by the thy1 sequence in less than 10% of 
cortical neurons (Feng et al., 2000), were obtained from The Jackson Laboratory (Stock 
number: 007788). Male BiozziABH mice were bred with female EGFP-M mice to obtain F1 
BiozziABH x GFP-M hybrids (reffered to as F1 hybrids). 
 
3.1.5 Human brain samples 
For histopathological analysis of multiple sclerosis tissue, human brain autopsies of male and 
female individuals with multiple sclerosis were obtained from the collection of the 
Department of Neuropathology at the Georg-August University, Göttingen, Germany. The 
use of the brain samples for scientific purposes was in accordance with the guidelines of the 




Changing station CS5 Type: 9CS53  Tecniplast S.P.A. 
Drill (K5plus Anlage)   Kavo    #4965/4911 
Drilling head     Gebr. Brassler GmbH&CoKG #H141A104 014 
Ear bars (Mouse) 60° Tip   David Kopf Instruments #922 
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Ear puncher, KN-292B, 2.0   Napox 
Forceps, 12cm    F.S.T    #11002-12 
Forceps, 2AM-SA    rubis, Switzerland 
Forceps     Aesculap   #BD043R 
Homogenizer pistil for 1,5ml tubes  neoLab   #6-1060 
Iris Scissors STR S/S 120MM  Aesculap   #BC064R 
Isoflurane system for anesthesia  tem sega 
Laminar flow Hera Safe Type: HS18 Heraeus   #50054579 
Micro knife     F.S.T    #10055-12 
Micro scissors, curved, 15,5cm, 6”  KLS martin group  #11-773-01 
Mouse Adaptor    Stoelting   #51624 
Needle holder, durogrip TC, 145mm  Aesculap   #BM015R 
Peristaltic pump Type: MC-MS/CA-4/8 Ismatec 
Scale PL602-S    Mettler Toledo 
Scissors     F.S.T    #14060-11 
Scissors     Hermle   #521 
Scissors     F.S.T    #14013-17 
Scissors     Hermle   #501 
Scissors     Hermle   #511 
Shaver      Tondeo   #100766 
Stereo microscope M60   Leica  
Stereotaxic device    Stoelting   #51600 
Tissue Forceps Slim – 1x2 Teeth  F.S.T    #11023-10 
TUB PTFE 2XHUBadapter Ga24x20mm length Chromatographie 
Service GmbH  #06586510 
Warming plate    MedaxHaska AG 
 
 Proteinbiochemistry 
3-D Shaker GyroTwister   Labnet 
Centrifuge Tubes, 50ml   KendroSorvall  #03146 
Circular mixer RM 5    Assistent   #348 
Electrophoresis Power Supply E802  Consort 
Homogenizer motor Type HS-30E Set witeg    #DH.WOS01011 
Homogenizer + PTFE pistil, 40ml, cylindric schuett-biotec GmbH  #3.213 402 
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Lab-Shaker RS-306 Type AG20  Infors AG HT 
Lab-Shaker Type LSR-V   Adolf Kühner AG 
Magnetic Stirrer RH basic 2   IKA    #3339000 
Mini-Protean 3 Cell Electrophoresis System Bio-Rad 
Nalgene Centrifuge Bottles, 250ml  Thermo Scientific  #3141-0250 
NanoDrop 2000c    Thermo Scientific  #ND-2000C 
Sonic Ruptor 400 Ultrasonic Homogenizer Omni International  #18-000-115 
Superspeed centrifuge Sorvall RC-5B Sorvall   #RC-5B 
Superspeed centrifuge Sorvall RC-5B Plus Sorvall   #RC-5B Plus 
Vaccum pump N86KN.18   KNF Lab Neuberger 
VMax Kinetic Microplate reader  Molecular Devices 
 
 Histology and immunohistochemistry 
CryostatCryoStar NX70   ThermoScientific  #957070 
Microscope, confocal LSM510Meta  Zeiss 
Microscope, light, CX41   Olympus 
Microscope, fluorescence, Axioskop 2 Zeiss 
Microtome, rotary HM 340 E  Thermo Scientific  #904090A 
Mirax Midi slide scanner   Zeiss 
Pascal pressure chamber, model S2800 Dako 
Tissue Embedding System TES 99  Medite    #TES99 
Tissue Processor Tissue-Tek VIP  Sakura 
Vibratome series 1000, Sectioning system TPI    #050418 
 
 Others 
Centrifuge, benchtop, 5415R   Eppendorf 
Centrifuge, benchtop, Model 4-16K  Sigma    #10475 
Freezer -20°C     Liebherr ProfiLine 
Fridge      LiebherrProfiLine 
Laminar flow MSC-Advantage 1.8  Thermo Scientific  #51026370 
Laminar flow BH 2006-D 195  Faster 
PCR 96 well Fast Thermal Cycler, Veriti Applied Biosystems 
Pipettes     Gilson 
Electrophoresis system, Sub-Cell GT BioRad   #170-4401 
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Electrophoresis system power supply BioRad    
ThermoMixer,MKR 13   HLC BioTech 
Ultra-low Temp.Freezer Forma 900 Series Thermo Scientific 




Animal Lancet 5mm    Goldenrod 
BD Microtainer SST Tubes   BD     # 365951 
Butterfly     BD Valu-Set   #387425 
Capillaries     HirschmannLaborgeräte #903 02 08 
Glass capillaries    BlaubrandintraMark  #7087 07 
Insulin syringe 0,3ml    BD Micro-Fine  #320837 
Insulin syringe 0,5ml    BD Micro-Fine  #320812 
Insulin syringe 1ml    BD Micro-Fine  #324811 
LuerLock syringes 3ml   BBraunOmnifix  #4617022V 
LuerLock syringes 5ml   BBraunOmnifix  #4617053V 
Needles 26G x 
3
/8 (0,45mm x 10mm) BD Microlance 3 #300300 
Needles 18G x 1
1
/2 (1,2mm x 40mm) BD Microlance 3  #304622 
Scalpels, surgicaldisposable   B.Braun   #5518075 
Sugi      Kettenbach   #31602 
Suture material    Ethicon   #6683H 
Syringe filter 0,22µm    TPP    #99722 
 
 Proteinbiochemistry 
Cuvettes     Sarstedt   #67.742 
Dialysis Cassette, Slide-A-Lyzer 3,5  Pierce    #66 110 
F96Maxisorp immunoplate   Nunc    #442404 
Poly-Prep Chromatography Columns, 5ml BioRad   #731-1550 
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 Histology and immunohistochemistry 
24 well cell culture plate, cellstar  Greiner bio-one  #662 160 
Embedding cassette, Uni-Cassette Biopsy green Sakura    #4174 
Microscope cover glasses, 22x22mm VWR    #631-1570 
Microscope cover glasses, 24x50mm VWR    #631-1574 
Microscope slides, Superfrost Plus  Menzel GmbH  #J1800AMNZ 
Microtome blade    Feather   #S35 
Razor blade, stainless steel, uncoated GEM    #62-0167 
Superglue, Cyanolit universal classic 3M    #241-D 
Tubes for cryo asservation   Semadeni   #1661 
 
 Others 
Combitips Plus 1.0ml    Eppendorf   #0030 069.234 
Combitips Plus 5.0ml    Eppendorf   #0030 069.250 
Eppendorf tubes, safe lock, 1.5ml  Eppendorf   #0030 120.086 
Eppendorf tubes, safe lock, 2.0ml  Eppendorf   #0030 120.094 
Falcon tubes, 15ml    Nunc    #366052 
Falcon tubes, 50ml    BD    #352070 
Micro Amp Fast reaction tubes  Applied Biosystems  #4358293 
Protein LoBind Tubes 0.5ml   Eppendorf   #022431064 
 
3.1.8 Software 
Fiji open source image processing software http://fiji.sc/; Schindelin et al., 2012  
GraphPadPrism 5.01    GraphPad Software, Inc. 
Huygens Essential    Scientific Volume Imaging 
LSM Image Browser Version 4.2.0.121 Zeiss 
LSM 510 Version 4.0 SP2   Zeiss 
NeuronStudio (Beta) Version 0.9.92  CNIC: http://research.mssm.edu/cnic/tools-
ns.html 
Pannoramic Viewer 1.15 RTM  3D Histech Ltd 
Tissue Studio Version 2.0.4   Definiens Developer XD 64 
 




3.2.1 Genotyping of EGFP-M positive animals 
Expression of EGFP in cortical neurons was determined by PCR. DNA was extracted from 
ear stamps with QuickExtract DNA Extraction Solution. The biopsy was roughly mixed in 
50 µl QuickExtract DNA Extraction Solution and incubated shaking for 15 min at 65°C 
followed by an incubation step at 98°C for 2 min. 1.5 µl extracted DNA from the supernatant 
was used as template for genotyping PCR (see Table 1 Genotyping PCR for EGFP expression 
and Table 2 PCR program for EGFP genotyping). 
The Primers GFP-geno Fwd and GFP-geno Rev (see all primer sequences in materials) were 
used for expression of the target sequence that results in a 173 bp PCR product. The Primers 
GFP-intctrl Fwd and GFP-intctrl Rev served as internal positive PCR control and result in a 
324 bp amplicon. EGFP positive animals showed a strong DNA band at 173 bp and a weak 
control amplicon at 324 bp, whereas EGFP negative animals showed only a strong DNA band 
at 324 bp.  
PCR products were separated by electrophoresis on a 2% agarose gel stained with SybrSafe 
DNA gel stain (1:10000). PCR products were visualized using ultraviolet light. 
 
Table 1 Genotyping PCR for EGFP expression  
Reagents Volume (12.5µl) 
Green GoTaq reaction buffer ,5 x 2.5 µl 
dNTPs (10 mM, each 2.5 mM) 0.5 µl 
Primers (10 µM) each 0.5 µl 
GoTaq DNA Polymerase 0.1 µl 
Water Molecular biology grade 5.9 µl 
DNA 1.5 µl 
 
Table 2 PCR program for EGFP genotyping 
Temperature (°C) Time (sec) Replication 
94 180 1x 
94 30 
35x 60 60 
72 60 
72 600 1x 
4 indefinite  
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3.2.2 Expression and purification of recombinant rat MOG1-125 
The N-terminal sequence of recombinant rat MOG1-125 (amino acids 1-125) was produced as 
previously described (Adelmann et al., 1995). His-tagged MOG1-125 was expressed in 
Escherichia coli (E.coli) strain BL21 and purified using Ni-NTA columns. A small amount of 
the bacterial glycerol stock was streaked onto a LB agar plate containing 40 µg/ml 
Kanamycin and grown at 37°C overnight. A preparatory culture of 6 ml LB Medium 
(40 µg/ml Kanamycin) was inoculated with a single colony of MOG1-125 expressing E.coli and 
incubated for 12 h at 37°C. A large-scale expression was performed in 2 l LB-Media 
(40 µg/ml Kanamycin) inoculated with 4 ml of the preparatory culture. Bacteria were 
incubated at 37°C until they reached an OD600 of 1. Then protein over expression was induced 
by addition of 1 mM IPTG and cultures were incubated for further 4 h at 37°C. Bacteria were 
harvested at 6000 rpm for 15 min at 4°C and dry pellets were stored at -20°C overnight. 
All purification steps (including centrifugations) were performed at 4°C. After resuspension 
of each bacteria pellet in 10 ml sonication buffer containing lysozyme, DNase I and protease 
inhibitor cocktail tablet (e.g. 70 ml sonication buffer + knife point lysozyme + 70 µl DNase I 
+ 1 Complete protease inhibitor cocktail tablet), cells were lysed by pulsed sonication. 
Sonication (1 puls/second) was performed six times for 1 min at intensity between 40-45%. 
Lysed bacteria suspensions were centrifuged at 11000 rpm and pellets were resolved in wash 
buffer. Further preparation and extraction of insoluble MOG1-125 present in inclusion bodies 
was performed using a homogenizer with a motorized pistil at 500 revolutions per minute. 
Suspensions were homogenized three times in wash buffer and one time in sonication buffer. 
After every homogenizing step suspensions were centrifuged at 14000 rpm. After the last step 
pellets were stored at -20°C. 
Each MOG1-125 pellet was resolved in 11 ml solubilisation buffer on a circular mixer for 
several hours and purified as follows. Nickel-NTA-columns contained 5 ml Talon Metal 
Affinity Resin that was equilibrated successively in 2 M, 4 M, 6 M urea solutions prepared in 
sonication buffer and finally in 8 M urea. In each equilibration step the resin was resolved in 
urea solution, mixed on a circular mixer for 20 min and centrifuged at 1000 rpm for 4 min. 
Supernatants were discarded. The resuspended MOG1-125 was loaded on the equilibrated resin 
and incubated for 2 h on a circular mixer. After loading, the resin was washed three times 
with 8 M urea for 20 min on a circular mixer and filled into the Poly-Prep Chromatography 
Columns. MOG1-125-loaded resin was washed further two times with 8 M urea and 5 ml 5 mM 
imidazole. MOG was eluted by addition of 40 mM imidazole. 1 ml fractions were collected 
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and MOG1-125 containing fractions were pooled (measured by a colour change using Bradford 
Protein Assay 1x Dye Reagent). 
Purified MOG1-125 was dialysed two times against 10 mM acetate buffer for 24 h. MOG1-125 
concentration was determined by a Bradford assay using Bradford Protein Assay 1x Dye 
Reagent and BSA standard protein dilutions. Protein degradation was analyzed by SDS-
PAGE and Coomassie staining. Finally MOG1-125 was diluted in water to a final concentration 
of 3 µg/µl and stored in aliquots at -80°C. 
 
3.2.3 SDS-PAGE 
SDS-PAGE was performed using a 4% stacking gel and 15% separation gel. A maximum of 
24 µg MOG1-125 were dissolved in TE buffer containing 1x sample loading buffer. MOG 
samples were heated at 95°C for 5 min and loaded into the stacking gel. A protein standard 
was used as molecular weight marker. The gel was initially run at 150 V in SDS running 
buffer until the lanes were parallel. Subsequently voltage was increased to 200 V for the 
separation. 
After electrophoresis gel was stained by 0.1% Coomassie stain solution for 5 min and washed 
several times with Coomassie destain solution until the lanes were visible. 
 
3.2.4 Animal experiments 
Animal experiments were performed in the Department of Neuropathology, University of 
Göttingen and the animal facility of the University Medical Center Göttingen in accordance 
with the guidelines and approved by the corresponding authorities in Niedersachsen 
(Germany) and in the Department of Pathology and Immunology, University of Geneva and 
in the animal facility of the University Medical Center Geneva in accordance with the 
guidelines and approved by the corresponding authorities in Geneva (Switzerland). 
Animals were kept in a 12:12 h light/dark cycle with food and water ad libitum.  
 
3.2.5 Blood sampling 
Animals were anaesthetized by inhalation of isoflurane and blood samples were taken by 
puncturing the submandibular vein on the day of immunization and the second and the fifth 
week after immunization. Animals were fixed tight at the head and a lancet was pricked into 
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the vein. Blood (~5 drops) was collected in a BD Microtainer tube. After 30 min of 
coagulating tubes were centrifuged at 15000 g for 1.5 min and stored at -20°C. 
 
3.2.6 Induction of EAE 
EAE was induced in eight to ten week old male and female BiozziABH mice and F1 hybrids 
of BiozziABH and EGFP-M mice. Animals were anesthetized by inhalation of isoflurane and 
immunized subcutaneously in all four flanks with 50 µg recombinant rat MOG1-125 emulsified 
in incomplete Freund’s adjuvant (IFA) supplemented with 10 mg/ml Mycobacterium 
Tuberculosis H37Ra in a total volume of 200 µl. Immunization was repeated one week later. 
Additionally 200 ng Pertussis toxin was administered intraperitoneally on both days of 
immunization and also the following day. Control animals were treated in an analogous 
manner but emulsions did not contain MOG. Clinical signs and weight were monitored daily 
from the tenth day. 
Clinical presentation was classified by an EAE scoring system ranging from score 0 to 5 (0: 
no overt clinical sings; 0.5: paresis of the tip of the tail; 1: complete tail paralysis; 1.5: 
difficulties to straighten up from a dorsal position; 2: hind limb paresis; 2.5: partial hind limb 
paralysis; 3: complete hind limb paralysis; 3.5: partial fore limb paralysis; 4: complete fore 
limb paralysis; 5: moribund). 
 
3.2.7 Intracerebral stereotactic injection 
Cortical lesions were induced by injection of 0.5 µg recombinant mouse TNF-α and 1500 U 
recombinant murine IFN-γ into the cortex three or five weeks after EAE induction as 
indicated in figure legends. For the surgical procedure animals were anesthetized using 
ketamine and xylazine containing acepromazine. 
BiozziABH mice with a clinical score or those who have been developed a clinical score were 
anesthetized by intraperitoneal (i.p.) injection of 67.5 mg/kg body weight ketamine followed 
by an injection of a mixture consisting of 8.8 mg/kg body weight xylazine and 1.35 mg/kg 
body weight acepromazine. BiozziABH mice without any clinical sign were anesthetized by 
i.p. injection of 75 mg/kg body weight ketamine followed by an injection of a mixture 
consisting of 9.75 mg/kg body weight xylazine and 1.5 mg/kg body weight acepromazine. 
F1 hybrids were anesthetized by i.p. injection of 90 mg/kg body weight ketamine followed by 
an injection of a mixture consisting of 11.7 mg/kg body weight xylazine and 1.8 mg/kg body 
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weight acepromazine. Anesthesia was administered in sterile PBS to maintain normal 
hydration during the surgical procedure.  
After loss of consciousness, mice were mounted on a stereotaxic device equipped with a 
mouse adaptor and mouse ear bars to hold the head fixed. The scalp was opened and a fine 
hole was drilled into the skull 0.6 mm caudal to the bregma and 2.2 mm lateral to the sagittal 
suture (Figure 1A). To avoid damage of the brain, the last part of the skull was removed 
carefully with a surgical micro knife giving access to the surface of the brain. A fine drawn 
glass capillary (outer diameter ~25 µm) was inserted 1.2 mm in an angle of 60° into the cortex 
(Figure 1B). These coordinates allow a targeted cytokine injection 0.6 mm caudal to the 
bregma, 1.2 mm lateral to the sagittal suture in a depth of 0.8 mm in the cortex. The addition 
of a blue marker dye (Monastral Blue) to the cytokine mixture allowed tracing of the lesion 
site. The cytokine mixture of 0.5 µg TNF-α and 1500 U IFN-γ was dissolved in sterile PBS 
and a total volume of 2 µl cytokine mixture was injected over a time period of 5 min. After 
the surgical procedure the skull was sealed by suturing the scalp and animals were kept warm 
until they woke up. In order to exclude tissue damage due to the penetration of the glass 




Figure 1 Strategy of targeted cortical EAE 
Defined coordinates for intracerebral stereotactic injection are shwon. (A) Schematic representation of 
the anatomical features after opening the scalp. The bregma is used as reference point for setting the 
stereotactic coordinates. A hole was drilled 0.6 mm caudal to the bregma and 2.2 mm lateral to the 
sagittal suture. (B) The glass capillary was inserted 1.2 mm in an angle of 60° into the cortex. These 
coordinates allowed the injection of the cytokines 1.2 mm lateral to the sagittal suture in a depth of 
0.8 mm. The cytokine mixture contained a blue marker dye allowing tracing of the lesion site. 
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3.2.8 Enzyme-linked immunosorbent assay (ELISA) 
Anti-MOG autoantibody titers were measured in naïve mice and two and five weeks after 
EAE induction. Each well of a 96-well Nunc plate was coated with 0.4 µg recombinant rat 
MOG1-125 in 1x PBS overnight at 4°C Wells were blocked with 5% BSA in 1x PBS for 1 h at 
room temperature and washed three times with 1x PBS. Sera were prediluted 100-fold in 
PBS-T0.05%/10% FBS. Beginning with the 100-fold sera dilution antibody titers were titrated 
in 3-fold dilutions in 11 steps in PBS-T0.05%/10% FBS and incubated for 2 h at room 
temperature in the well plate. Autoantibodies were detected by a goat-anti-mouse IgG-
peroxidase conjugate (1:10000) for 1 h at room temperature and developed with 50 µl TMB-
US per well for 5 min. The reaction was stopped by addition of 50 µl 1 N sulfuric acid and the 
optical density was measured at 450 nm. After both antibody incubation steps plates were 
washed at least four times with PBS-T0.05%. Threshold for seropositivity was defined as an 
absorption value higher than a control animal achieved in a 300-fold dilution. 
 
3.2.9 Histology of mouse brain tissue 
3.2.9.1 Tissue processing 
3.2.9.1.1 Perfusion and sectioning 
Tissue was analyzed histologically three days and three weeks after intracortical cytokine 
injection. For this purpose, animals were anaesthetized intraperitoneally with a lethal dose of 
Esconarkon. After loss of consciousness mice were perfused transcardially with 15 ml ice-
cold 1x PBS followed by 50 ml 4% ice-cold paraformaldehyde over 10 min (perfusion 
velocity ~6.5 ml/min) using a peristaltic pump. Brains were carefully dissected from the skull 
and postfixed in 4% paraformaldehyde for 24 h at 4°C. Brain tissue was then transferred into 
1x PBS. Coronal slices of ~3 mm containing the injection site (Figure 2) were cut out and 
either embedded in paraffin using an automated tissue processor (gradually dehydration to 
paraffin) or cryoprotected in Tissue-Tek and stored at -20°C or -80°C. Tissue obtained from 
BiozziABH or EGFP-negative F1 hybrids was embedded in paraffin whereas tissue from 
EGFP-positive F1 hybrids was cryoprotected. Paraffin-embedded tissue was trimmed until the 
injection site (recognized by the blue marker dye within the tissue) and then 1-2 µm thin 
coronal sections containing the lesion were mounted on microscope slides. Sectioning was 
performed using a rotary microtome. Tissue slices obtained from EGFP-positive F1 hybrids 
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were incubated in 30% sucrose for 3 days at 4°C, embedded in Tissue-Tek and stored at -
20°C. Cryosections of 30 µm thickness were cut directly before staining using a cryostat. 
 
 
Figure 2 Coronal sectioning of the injection site 
A coronal slice including the injection site of about 3 mm thickness was carefully cut out from the 
fixed brain as shown in the scheme. The exact injection site was visible on the surface of the brain due 
to the blue marker dye. The coronal slice was either embedded in paraffin or cryoprotected for further 
trimming to the lesion and obtaining slices for histological analyses. 
 
3.2.9.1.2 Deparaffinizationa and rehydration 
Paraffin-embedded tissue sections were incubated in a dry oven at 55-60°C overnight. 
Deparaffinization was performed successive in four bath of Ultraclear for 10 min respectively 
and rehydrated by incubating the slides twice in 100% ethanol, one time in 90% ethanol, one 
time in 70% ethanol and one time in 50% ethanol in water for 5 min respectively and finally 
washed in distilled water.  
For dehydration tissue sections were incubated in the same bath in a reversed order for 5 min 
respectively, mounted in Ultrakitt and coverslipped. 
 
3.2.9.2 Histochemistry 
3.2.9.2.1 Bielschowsky’s silver staining 
Axon density was determined by Bielschowsky silver staining. Deparaffinized tissue sections 
were washed with distilled water and afterwards incubated in 20% silver nitrate solution for 
20 min. Following washing in distilled water, sections were incubated in 20% silver nitrate 
solution containing 5% ammonium hydroxide for 15 min protected from light. Sections were 
transferred in 0.6% ammonium hydroxide and swayed. 1/35 volume of the developer solution 
was added to the 20% silver nitrate solution containing 5% ammonium hydroxide while 
stirring. Subsequently the sections were transferred into the solution and developed until the 
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colour of the sections turned brown. Following washing in distilled water, sections were 
incubated in 2% sodium thiosulfate solution for 2 min. Finally sections were washed with tap 
water, dehydrated (as described above), mounted in Ultrakitt and coverslipped. 
 
3.2.9.3 Immunohistochemistry 
3.2.9.3.1 Antigen retrieval for CD3, Mac-3, NeuN in paraffin-embedded sections 
Immunostainings for some antigens required an antigen retrieval step in order to unmask 
antigenic sites that were masked during fixation  
Rehydrated tissue sections were treated for 30 sec at 125°C under pressure (20-22 psi) in 1x 
citrate buffer (pH = 6) in a Pascal pressure chamber. Antigen retrieved sections were allowed 
to cool down, washed in distilled water and subsequently stained. 
 
3.2.9.3.2 Immunohistochemistry for MBP and NeuN in paraffin-embedded sections 
Antigens in paraffin-embedded sections that were recognized by a primary mouse or rabbit 
antibody were stained using the Dako EnVision System. All staining steps were performed at 
room temperature in a humid chamber. Sections were washed in 1x Dako wash buffer for 
2 min and blocked with Dako Real peroxidase blocking solution for 5 min. After two washing 
steps in 1x Dako wash buffer for 5 min, sections were treated with the primary antibody 
diluted in Dako Real antibody diluent for 1 h. Primary antibody dilutions are as follows: 
1:1000 for MBP and 1:50 for NeuN. 
After washing with 1x Dako wash buffer for 2 min, Dako EnVision HRP labeled polymer 
anti-rabbit or anti-mouse IgG secondary antibody was added for 30 min. After that, sections 
were washed twice with 1x Dako wash buffer for 5 min and developed with DAB-containing 
developer solution (20 µl DAB chromogen + 1 ml DAB substrate buffer). Tissue sections 
were washed with tap water followed by counterstaining with Mayer’s Hämalaun. Finally, 
sections were dehydrated (as described above), mounted in Ultrakitt and coverslipped. NeuN-
staining required additionally a Fab blocking and FBS blocking step before primary antibody 
treatment. Fab blocking was performed by incubating the sections with Fab Fragment Goat-
anti-mouse IgG diluted 1:50 in Dako Real antibody diluent after peroxidase blocking for 1 h. 
Subsequently sections were blocked with 10% FBS diluted in Dako Real antibody diluents for 
20 min and stained with the primary antibody thereafter. NeuN sections were not 
counterstained. 
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3.2.9.3.3 Immunohistochemistry for Mac-3 and CD3 in paraffin embedded sections 
Antigens in paraffin-embedded sections that were recognized by a primary rat antibody were 
stained using a Biotin-Streptavidin System from Dako. All staining steps were performed at 
room temperature in a humid chamber. Peroxidase blocking and incubation with primary 
antibodies was performed as described above. Primary antibody dilutions are as follows: 
1:100 for CD3 and 1:200 for Mac-3. 
After washing with 1x Dako wash buffer for 2 min, tissue sections were incubated with a 
biotinylated Rabbit Anti-Rat antibody diluted 1:250 in Dako Real antibody diluent for 15 min. 
After two washing steps with 1x Dako wash buffer for 5 min, Dako Real Streptavidin 
Peroxidase (HRP) was added for 15 min. Subsequently the sections were washed twice with 
1x Dako wash buffer for 5 min and developed with DAB-containing developer solution as 
described above. Tissue sections were washed with tap water followed by counterstaining 
with Mayer’s Hämalaun. Finally, sections were dehydrated (as described above), mounted in 
Ultrakitt and coverslipped. 
 
3.2.9.3.4 Immunohistochemistry for MBP in EGFP positive cryosections 
Cryosections (40 µm) were cut and directly transferred in a 24 well cell culture plate 
containing 1x PBS. Sections were stained free-floating (protected from light) at room 
temperature on a shaker if not indicated otherwise. Sections were washed three times with 1x 
PBS for 10 min, treated for 15 min with cooled methanol at -20°C and washed three times 
with 1x PBS for 15 min. Sections were blocked in 1x PBS containing 10% FBS and 0,5% 
Triton X-100 for 1 h and treated with the primary antibody diluted in 1x PBS containing 
1% FBS and 0.5% Triton X-100 overnight. Primary antibody dilution was 1:200 for MBP. 
After washing three times in 1x PBS for 10 min, sections were treated with the secondary 
fluorescence labeled (Alexa Fluor 555) goat-anti-rabbit IgG (H+L) antibody diluted 1:200 in 
1x PBS containing 1% FBS and 0.5% Triton X-100 for 3 h. Sections were washed three times 
with 1x PBS for 30 min. DAPI was stained 1:10000 in 1x PBS for 15 min and sections were 
washed three times with 1x PBS for 10 min. Sections were stretched in distilled water 
containing 0.1% gelatin and 10% ethanol and put on slides, mounted in Fluoprep and 
coverslipped. 
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3.2.10 Histology of human brain tissue 
3.2.10.1 Human tissue collection 
Tissue samples were collected from four autopsy cases with multiple sclerosis and three 
control autopsy cases without neurologic disease. Brains were stored immediately after death 
in 4% formalin with salt for one to two month. Brain tissue containing the cortex was 
dissected at one topographic area, namely frontotemporal lobe, of both hemispheres. Tissue 
blocks were split into two parts and one part was embedded in paraffin and stained for MBP 
to assess cortical demyelination (MBP staining was performed according to the MBP staining 
protocol for mice with the exception, that human sections required the above mentioned 
antigen retrieval in 1x citrate buffer using a Pascal pressure chamber). The second part of the 
block was processed for Golgi-Cox impregnation to study cortical dendritic pathology. 
 
3.2.10.2 Golgi-Cox impregnation 
In order to assess dendritic pathology in human brain tissue a Golgi-Cox impregnation was 
performed. Formalin-fixed tissue blocks were washed three times with 0.4 M Soerensen 
phosphate buffer (pH = 7,4) at room temperature for washing out the fixative. Subsequently 
the blocks were incubated afloat in a solution consisting of 5% potassium dichromate, 5% 
mercury chloride and 5% potassium chromate for three weeks protected from light at room 
temperature. After postfixation in 10% formalin for 1 h at 37°C, tissue blocks were cut in 
70 µm sections using a vibratome. Tissue slices were treated with 5% sodium carbonate for 
2 min at room temperature, washed with distilled water and mounted on gelatin-coated slides. 
Sections were mounted in Ultrakitt and coverslipped for further analyses. 
 
3.2.11 Image acquisition, processing  and analyses of histological tissue sections 
Brightfield histological slides were scanned in an automated mode with a Mirax Midi slide 
scanner equipped with a Plan-Apochromat 20x/0.8 objective and detected with a Marlin F-
146C IRF Medical camera. Images were either analyzed manually using Pannoramic Viewer 
1.15 or automatically in Tissue Studio Version 2.0.4. 
Cortical de- and remyelination was analyzed in scanned MBP-stained paraffin sections on the 
ipsilateral (injected) hemisphere using Pannoramic Viewer 1.15 by measuring the area of 
demyelination and the length of subpial demyelination.  
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Axonal density was analyzed on the ipsilateral hemisphere in Bielschowsky’s silver-stained 
tissue sections. Myelin density was determined in adjacent MBP-stained sections. Axon and 
myelin density was measured in cortical layer I and II (depth of 150µm from the pial surface 
into the cortex) with a counting grid under a light microscope at 40x magnification. 
Intersections of axons and myelin with the counting grid were counted in four visual fields 
alongside the pial surface. One visual field encompassed an area of 200 µm x 150 µm. 
Inflammatory T cell infiltrates were determined in scanned CD3-stained paraffin sections, 
total activated, round/oval-shaped and foamy macrophages/microglia were assessed 
respectively in scanned Mac-3-stained sections on the ipsilateal hemisphere using Pannoramic 
Viewer 1.15. The number of cells was counted in different cortical layers, namely cortical 
layers I+II, layer III+IV and V of at least 0.15mm
2 
respectively or in the combined cortical 
layers I-V of at least 0.45mm
2
.  
Cortical thickness was measured paramedially in scanned NeuN-stained paraffin sections on 
both hemispheres using Pannoramic Viewer 1.15. 
Neuronal density was analyzed in scanned paraffin sections stained for neuronal nuclei 
(NeuN) on the ipsilateral and contralateral hemisphere in cortical layers II, III+IV and V as 
well as in combined cortical layers II-V using Tissue Studio Version 2.0.4 in comparable area 
sizes as described above for inflammatory infiltrates. Tissue Studio counted NeuN
+
 neurons 
automatically by detection of DAB-stained, brown nuclei and perikarya in marked regions of 
interest. 
Dendrites and dendritic spines in mice were visualized in MBP-stained cryosections of EGFP 
positive F1 hybrids. Segments of the main dendritic branch extending upright to the surface of 
the brain of neurons in cortical layer V-VI were imaged in distinct distances from the soma. 
Images of 44 µm x 44 µm were aquired using a confocal laser scanning microscope 
(LSM510Meta) equipped with an upright Zeiss Axio Imager Z1 microscope. Images were 
captured with a Plan Apochromat 63x 1.4 Oil DIC objective using an Argon/2 laser (488 nm) 
in a coupled detector. EGFP-expressing neurons were detected by emitted fluorescence. To 
achieve ideal sampling for image processing (deconvolution) confocal stacks were scanned in 
z-direction in an interval of 200 nm to obtain an overlap of 75%. Each frame was scanned 
four times and averaged. Voxel sizes of 75 nm x 75 nm x 200 nm were obtained using a 3x 
zoom. Images were deconvolved using Huygens Essential to improve resolution laterally and 
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axially. Dendrites and dendritic spines were analyzed using NeuronStudio (Beta) Version 
0.9.92. Dendritic shaft radii, general spine densities, spine densities of specific spine shapes 
and spine head volumes were computed. Spines were calssified according to their 
morphologic characteristics into mushroom, stubby or thin by using the default values in 
NeuronStudio (Beta) Version 0.9.92 (CNIC). In detail, spines that have a head to neck 
diameter ratio greater than 1.1 were classified as thin or mushroom. Spines that meet that 
criteria and have a head diameter greater than or equal to 0.35 µm were classified as 
mushroom, otherwise as thin. Spines that have a head to neck diameter ratio smaller than or 
equal to 1.1 and a spine length to head diameter ratio greater than 2.5 were classified as thin, 
otherwise as stubby. Changing radii were measured by the sum of slopes between radii from 
two adjacent nodes divided by the dendritic length meaning the more irregularly the dendrite 
the more variable is the radius and the higher the sum of slopes for an imaged dendritic 
segment. 
Dendritic pathology in MS cases was investigated in Golgi-Cox-impregnated sections. 
Dendrites were classified to be located within the lesion, at the lesion border or in the NAGM 
according to the MBP staining on adjacent sections and localization of the neuronal soma. 
Dendrites of cortical layer IV-VI neurons were imaged. In detail, basal segments of the main 
dendritic branch extending upright to the surface of the brain were studied in 50 µm 
successive distances from the soma. Image acquisition was performed as described above. 
Golgi-Cox-impregnated structures were detected by the reflected laser light. For this purpose, 
the microscope was set up only with a 80/20 beam splitter. Image sampling and processing 
(deconvolution) was performed as described above. Dendritic spines and branches per 
dendritc length were counted and dendritic width was measured using Fiji software.  
 
3.2.12 Statistical analyses 






4.1 Development of a targeted EAE model of cortical demyelintion 
EAE was induced in BiozziABH mice and F1 hybrids generated from BiozziABH and EGFP-
M mice. Animals were immunized twice against recombinant MOG1-125 in CFA. Controls 
were treated with CFA alone. Cortical demyelination was elicited five and three weeks after 
the first immunization in BiozziABH and F1 hybrids respectively by the intracortical injection 
of TNF-α and IFN-γ as described above (Figure 1). Control mice were treated equally. Brain 
tissue was collected three days and three weeks after lesion induction for histological analyses 
(Figure 2). Injection site was recognized by a blue marker dye. Clinical EAE scores (if 
occurred) are not shown as they reflect lesions affecting the spinal cord but not the here 
investigated cortical GM. 
 
4.2 Immunization with MOG1-125 leads to high antibody titers in serum 
Myelin-specific autoantibodies may play a crucial role in triggering demyelination in the 
cerebral cortex. Therefore, mice were immunized with recombinant MOG1-125 instead of 
MOG-peptide. Autoantibody titers against MOG1-125 were measured two and five weeks after 
immunization in sera of BiozziABH and F1 hybrids using ELISA (Figure 3). MOG-
immunized BiozziABH (Figure 3A) and F1 hybrids (Figure 3B) developed autoantibody titers 
from week two after the first immunization that increased slightly in BiozziABH and 
remained stable in F1 mice to week five. In naïve mice and control animals that were treated 










Figure 3 MOG1-125-immunization induces high autoantibody titers 
Autoantibody titers against MOG1-125 were measured at indicated timepoints after immunization in (A) 




4.3 Cortical demyelination is primarily located at subpial areas, reveals partial 
remyelination and mimics cortical MS lesions 
Demyelinated lesions were induced by intracortical (i.c.) injection of the proinflammatory 
cytokines TNF-α and IFN-γ five weeks and three weeks after immunization against MOG1-125 
in BiozziABH and F1 hybrids respectively. Cortical demyelination as well as remyelination 
were assessed on MBP-stained paraffin sections on the injected (ipsilateral) hemisphere three 
days and three weeks after cytokine injection respectively. Induced cortical plaques could be 
classified as active lesions three days after cytokine injection as evidenced by the presence of 
myelin-laden cells (Figure 4). These cells, corresponding to macrophages/microglia, 
phagocytozed myelin debris as indicated by cytoplasmic colocalization of MBP
+
 fragments at 
the lesion border of demyelinated cerebral cortex. Generally, MBP-laden 
macrophages/microglia are indicative for active demyelination. 
Furthermore, cortical demyelination was detected in MOG-immunized BiozziABH as well as 
F1 hybrids three days after lesion induction but not in controls (Figure 5). Both experimental 




Figure 4 Active demyelination can be observed three days after cytokine injection 
A representative picture of a cortical lesion border (marked by the dotted line) showing demyelination 
at the top and the surrounding NAGM at the bottom in a MBP-stained section. Note at the lesion 
border phagocytes containing MBP
+
 fragments can be observed (boxes a, b, and c, arrows in the 







Topologically, lesions primarily affected subpial areas with demyelination extending from the 
pial surface mostly to cortical layer II (Figure 5). These lesions spread laterally as band-like 
demyelinated area. Similar cortical lesion types were seen primarily in chronic MS patients 
and were reminiscent of the described lesion type III affecting subpial areas (Bo et al., 2003b; 
Peterson et al., 2001). Purely intracortical lesions could as well be detected and were observed 
as small round-shaped demyelinated areas, centered on blood vessels (Figure 5). This lesion 
type was less frequently observed than subpial demyelination and accounted for only 1% of 
the total demyelinated area in BiozziABH mice and 4% of the total demyelinated area in F1 
hybrids. 
Targeted cortical demyelination was quantified as the area of demyelination (subpial as well 
as intracortical) in MOG-immunized BiozziABH and F1 hybrids three days and three weeks 
after cytokine injection (Figure 5). The extent of demyelination was similar between 
BiozziABH (0.51 ± 0.09 mm
2
, Figure 5A) and F1 hybrids (0.49 ± 0.11 mm
2
, Figure 5B) at 
day three. Three weeks after cytokine injection both experimental groups showed a significant 
reduction in demyelinated area and a partial restoration of myelin in the ipsilateral cortex, 
indicating a transient cortical demyelination (Biozzi: 0.02 ± 0.003 mm
2
, F1 hybrids: 
0.10 ± 0.02 mm
2
, Figure 5A and B). The residual area of demyelination at week three was 
significantly smaller in BiozziABH mice compared to F1 hybrids (p = 0.0159, statistical 
evaluation was performed as indicated in the legend of Figure 5). Therefore, remyelination in 
BiozziABH mice is more efficient than in F1 hybrid mice. The intracerebral injection of PBS 
alone led to no signs of demyelination in a MOG-immunized animal (data not shown). 
In addition to the demyelinated area the length of subpial demyelination was analyzed on the 
same MBP-stained sections. The lateral extension of subpial demyelination was comparable 
in BiozziABH (3.60 ± 0.51 mm, Figure 5A) and F1 hybrids (3.52 ± 0.31 mm, Figure 5B) 
three days after intracortical cytokine injection. According to the reduced area of 
demyelination the length of subpial demyelination was also significantly reduced in both 
animal strains three weeks after lesion induction. Again BiozziABH showed a significant 
more efficient regeneration (BiozziABH 0.14 ± 0.01 mm and F1 hybrids 0.81 ± 0.14 mm, 
p = 0.0159, statistical evaluation was performed as indicated in the legend of Figure 5A and 
B). 
Since similar extents of cortical demyelination were observed in BiozziABH and F1 hybrids 
and the intercross with C57BL6/J animals could allow the use of transgenic animals as e.g. 
reporter strains in F1 hybrids, this work further focused on the analysis of the effects of de- 
































Figure 5 Targeted cortical demyelination is followed by partial remyelination 
Representative pictures and quantification of demyelination (area and subpial length) in (A) 
BiozziABH (n = 4 animals per group) and (B) F1 hybrids (n = 5 animals per group) at indicated time 
points after cytokine injection revealed widespread cortical demyelination (indicated by the dotted 
line) at three days followed by partial remyelination at three weeks. Injection site is marked by an 
asterisk. Data are shown as mean + SEM. Statistical evaluation was performed by a Mann-Whitney 




4.4 Axonal preservation but incomplete remyelination in targeted cortical 
demyelinated lesions 
Although remyelination occured within three weeks after cytokine injection this process 
remained incomplete as seen by a less dense myelin staining compared to controls (Figure 6) 
and residual small demyelinated areas (Figure 5). In order to investigate whether the partial 
remyelination may be due to axonal loss, axonal density was determined in Bielschowsky-
stained paraffin sections in F1 hybrids in cortical layer I-II during de- and remyelination on 
the ipsilateral hemisphere (Figure 6C). Furthermore myelin density was assessed equally in 
de- and remyelinated cortex in adjacent MBP-stained paraffin sections (Figure 6A). 
Afterwards, the proportion of myelinated axons was determined by calculating the ratio of 
myelin intersections to axon intersections (Figure 6E). Corroborating the previous analyses of 
the extent of demyelination, during ongoing demyelination three days after cytokine injection 
subpial myelin density in cortical layer I-II was significantly reduced in MOG-immunized F1 
hybrids (10.35 ± 2.94 MBP
+
 intersections/field) compared to control animals (39.90 ± 3.15 
MBP
+
 intersections/field). Three weeks after cytokine injection myelin density significantly 
regenerated in MOG-immunized animals (22.35 ± 3.35 MBP
+
 intersections/field) compared 
to demyelinated animals. However, the density of myelin was still significantly decreased 
compared to control animals (42.00 ± 1.50 MBP
+
 intersections/field) similar to the above-
described results (Figure 6A and B). The axon density was comparable in MOG-immunized 
and control F1 hybrids at all timepoints with 104.10 ± 1.15 axon intersections/filed in MOG-
immunized F1 hybrids in comparison to 107.70 ± 4.68 axon intersections/field in controls at 
three days after cytokine injection. Three weeks after lesion induction MOG-sensitized F1 
hybrids revealed 98.95 ± 6.01 axon intersections/field compared to 97.15 ± 3.84 axon 
intersections/field in controls (Figure 6C and D), clearly demonstrating that no significant 
axonal degeneration occurred during de- and remyelination. Accordingly, the proportion of 
myelinated axons in demyelinated cortex (8.49 ± 3.13%) is significantly decreased compared 
to controls at day three (37.49 ± 3.91%) and to remyelinated cortex (22.79 ± 3.58%) three 
weeks after cytokine injection. Nevertheless, the proportion of myelinated axons is still 
significantly reduced in remyelinated cortex in comparison to controls (43.36 ± 1.44%) at 
three weeks after lesion induction (Figure 6E), indicating that only approximately 50% of 






Figure 6 Axonal preservation in incomplete remyelinated lesions 
Representative pictures of (A) MBP- and (C) Bielschowsky-stained sections are depicted at indicated 
time points after cytokine injection in F1 hybrids. Quantification of myelin density (B), axonal density 
(D), and proportion of myelinated axons (E) in subpial areas revealed demyelination at three days 
followed by incomplete remyelination (arrows in A) at three weeks and preservation of axons at all 
indicated time points after lesion induction. All groups included n = 5 animals except for the MOG 
day 3 group of axon density and myelinated fraction (n = 4 animals). Data are represented as mean + 
SEM. Statistical evaluation was performed by a Mann-Whitney test. * indicates statistical significance 






4.5 Cortical inflammation is transient after lesion induction 
4.5.1 Infiltration of T cells during demyelination 
Acitve cortical demyelination was shown to occur on a background of inflammation in MS 
patients (Lucchinetti et al., 2011) as well as in rats (Merkler et al., 2006b). Therefore, 
inflammatory infiltrates of T cells were assessed in CD3-stained paraffin sections in different 
cortical areas in the injected hemisphere three days and three weeks after intracortical 
cytokine injection (Figure 7). Cortical areas comprising cortical layer I+II, III+IV and V were 
analyzed separately and combined (cortical layer I-V). Infiltrating T cells were readily 
detectable in all analyzed cortical layers three days after cytokine injection and a small 
number of T cells was still visible at three weeks (Figure 7A, cortical layer I+II are shown). 
Quantitative analysis of cortical layers I-V proved the number of infiltrating T cells 









) at day three 
(Figure 7B). Three weeks later the T cell number significantly decreased in MOG-sensitized 









) (Figure 7B). Subanalysis investigating distinct cortical layers showed no overt 





), where demyelination is mostly prominent, compared to other cortical layers (layer 









However, T cell numbers were significantly higher in all analyzed cortical areas in MOG-









































 for controls) (Figure 7C). 
Intracerebral injection of PBS alone in a MOG-immunized mouse led to infiltration of a low 
number of T cells around the injection site and the needle track at three days (data not shown). 
Thus, cortical demyelination was accompanied by a transient T cell infiltration and T cells 






Figure 7 Transient CD3
+
 T cell infiltration during demyelination 
(A) Representative pictures of CD3-stained T cells (marked by arrows) in F1 hybrids are depicted at 
indicated time points after lesion induction. Quantification of the number of T cells in cortical layer I-
V (B) and specific cortical layers (C) revealed a transient increase of T cells throughout the ipsilateral 
hemisphere in MOG-sensitized mice at day three after lesion induction. (B) Data are shown as mean + 
SEM (n = 5 animals per group). For statistical evaluation a Mann-Whitney test was performed. * 
indicates statistical significance (** = p<0.01). (C) Data are expressed as mean + SD (n = 5 animals 
per group). A two-way ANOVA followed by a Bonferroni post hoc analysis was performed for 
statistical analysis. * indicates statistical significance (* = p<0.05, ** = p<0.01, *** = p<0.001). 
nd = not detected. 
 
 
4.5.2 Different morphological phenotypes of macrophages/microglia are present in 
demyelinated cortex 
The presence of different morphological activated macrophages/microglia phenotypes might 
represent functional variety. A hallmark for ongoing demyelination is the presence of myelin-
phagocytosing and foamy macrophages. Therefore, total numbers of activated 
macrophages/microglia as well as morphologic round-shaped and foamy 
macrophage/microglia phenotypes were analyzed respectively in Mac-3-stained paraffin 
sections in distinct cortical layers of the ipsilateral hemisphere three days and three weeks 
after lesion induction as described above (Figure 8). The Mac-3 antigen is expressed on the 
surface of activated macrophages/microglia but much less on restint microglia. Different 







Figure 8 Different morphological phenotypes of macrophages/microglia during demyelination 
(A) Representative pictures of Mac-3
+
 activated macrophages/microglia in subpial areas (left) and 
different reactive phenotypes (right). Quantification of total activated macrophages/microglia (B, C) 
and subdivision into round/oval-shaped (D, E) and foamy (F, G) phenotypes in cortical layer I-V or 
indicated cortical layers. Note the number of activated macrophages/microglia and especially 
round/oval-shaped and foamy phenotypes was increased during demyelination in MOG-immunized F1 
hybrids at day three. (B, D, F) Data are shown as mean + SEM (n = 5 animals per group). For 
statistical evaluation a Mann-Whitney test was performed. * indicates statistical significance 
(** = p<0.01). (C, E, G) Data are expressed as mean + SD (n = 5 animals per group). A two-way 
ANOVA followed by a Bonferroni post hoc analysis was performed. * indicates statistical significance 




High numbers of activated macrophages/microglia were detectable in the cortex of MOG-
immunized mice and controls three days after cytokine injection which then decreased at three 
weeks (Figure 8A). Quantitative analysis revealed significantly more numbers of activated 









) at day three and 
in comparison to both experimental groups three weeks after lesion induction (MOG: 








) (Figure 8B). 
Analyses of distinct cortical areas showed that the number of total activated 
macrophages/microglia was significantly higher in MOG-immunized mice in cortical layer 


















) three days after cytokine injection. In cortical layer V comparable numbers of 









) (Figure 8C). Considering 
round/oval-shaped activated macrophages/microglia similar results were obtained. In cortical 
layer I-V significantly more round/oval-shaped activated macrophages/microglia were 




) compared to controls 




) during demyelination. Only a few round/oval-shaped 
activated macrophages/microglia remained in the cortex within three weeks in MOG-




) but were almost absent in controls 




) (Figure 8D). In all distinct cortical layers round/oval shaped 














) but still significantly increased compared to 













) three days after lesion induction (Figure 8E). Foamy 
macrophages/microglia that were indicative for phagocytosing myelin debris thereby 
representing ongoing demyelination were mostly seen in MOG-immunized F1 hybrids three 
days after cytokine injection in cortical layers I-V. This group showed significantly higher 
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, Controls: not detected) (Figure 8F). Detailed analyses regarding distinct 
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). In all other experimental groups they were nearly completely absent (Figure 
8G). The intracerebral injection of PBS alone in a MOG-sensitized mouse revealed a few 
activated macrophages/microglia close to the injection site and needle track three days later 
(data not shown). Due to the injection of proinflammatory cytokines in control mice, 
macrophages/microglia were on alert and expressed the activation marker Mac-3. However, 
since round/oval-shaped and foamy phenotypes are virtually not present in control animals 
this indicated that these cells are differentially activated. Round/oval-shaped and especially 
foamy macrophages seemed to contribute to demyelination. 
 
4.6 Cortical EAE reveals no neuronal loss  
4.6.1 Cortical thickness is slightly reduced after remyelination 
Cortical thinning is a general sign for cortical atrophy. Cortical thickness was measured 
paramedially in NeuN-stained paraffin sections in the ipsi- and contralateral hemisphere of F1 
hybrids as indicated (Figure 9A). MOG-immunized F1 hybrids showed a statistical trend for a 
reduced paramedial cortical thickness three weeks after lesion induction on the ipsilateral 
(1191 ±70.59 µm, p = 0.056 compared to MOG day three) and contralateral 
(1267 ± 60.19 µm, p = 0.15 compared to MOG day three) hemisphere compared to both 
hemispheres in MOG-immunized mice at day three (ipsilateral: 1416 ± 30.33 µm, 
contralateral: 1395 ± 12.09 µm). Controls revealed comparable cortical thicknesses three days 
(ipsilateral: 1341 ± 54.61 µm, contralateral: 1368 ± 73.04 µm) and tree weeks (ipsilateral: 
1328 ± 62.04 µm, contralateral: 1359 ± 46.99 µm) after cytokine injection in comparison to 






Figure 9 Slightly reduced paramedial cortical thickness after remyelination 
(A) Representative pictures of NeuN-stained tissue sections and measurement of paramedial cortical 
thickness in F1 hybrids. Injection site is marked by the asterisk. (B) Quantitative analysis revealed a 
trend for reduced cortical thickness in MOG-immunized mice three weeks after cytokine injection on 
the ipsilateral hemisphere. Data are expressed as mean + SEM (n = 5 animals per group). 
 
4.6.2 Neuronal density is not reduced in targeted EAE 
Evaluation of a potential loss of cortical neurons was assessed by counting the number of 
cortical NeuN
+
 neuronal nuclei automatically in paraffin sections on both hemispheres. 
Neurons were counted in cortical layers II, III+IV and V respectively and combined (cortical 
layer II-V) and neuron detection was performed as shown in Figure 10A. MOG-immunized 
animals did not reveal a loss of cortical neurons in any analyzed cortical area at all time points 
(data not shown). Depicted is the neuronal density of cortical layer II-V. According to the 
absence of axonal degeneration in MOG-immunized mice, no loss of neurons on both 
hemispheres could be observed three weeks after cytokine injection (ipsilateral: 








) compared to 
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Figure 10 Neuronal density is not altered during de- and remyelination 
(A) Neuronal density was analyzed by counting NeuN
+
 cells automatically in the ipsi- and 
contralateral hemisphere in areas of cortical layers II-V. (B) Neuronal cell counts revealed comparable 
numbers of NeuN
+
 cells in both hemispheres at all indicated timepoints and groups. Data are shown as 
mean + SEM (n = 5 animals per group). 
 
4.7 Visualization and shape analysis of dendrites and spines in the cerebral 
cortex of mice 
Neurons receive signaling input via their dendrites and spines. During neurodegenerative 
processes loss of synaptic transmission therefore alter the functional properties of neurons. 
Previous studies showed that in MS patients loss of synaptic density in demyelinated 
hippocampi (Dutta et al., 2011) and leukocortical lesions (Wegner et al., 2006) can occur. 
However, it remains still unclear at which cellular level such alterations affect dendrites and 
spines. The primary aim of this work was, therefore, to establish a method that would enable 
to study alterations in neuronal structures as dendrites and dendritic spines in the cerebral 
cortex at subcellular level with high spatial resolution. In this approach a computational 
assisted method was used with which neuronal structures can be reconstructed and alterations 
in spine densities, shapes or dendritic irregularities can be detected. In order to visualize 
dendrites and dendritic spines, tissue from EGFP
+
 F1 hybrids was analyzed since these mice 
expressed EGFP in less than 10% of cortical neurons allowing the tracking and reconstruction 
of distinct cortical dendrites with high spatial resolution (Feng et al., 2000). Main dendritic 
branches of neurons located in the cortical layer V-VI were imaged in distinct distances from 
the soma using a confocal laser scanning microscope and images were deconvolved (Figure 
11). High-resolution imaging revealed detailed dendritic structures like dendritic branches 
(Figure 11B) and spines (Figure 11C and D). Zooming in allowed even the detection of single 




















Figure 11 Visualization of dendritic branches and spines 
(A) Confocal image of an EGFP
+
 cortical neuron with the main dendritic branch extending upright to 
the brain surface. (B-D) High resolution images revealed dendritic branches (yellow arrows) and 
spines. (E-G) Zooming in allowed detection of single spines (red arrows). 
 
Three-dimensional (3D) reconstruction of such neuronal processes was performed using 
NeuronStudio (CNIC) (Figure 12). NeuronStudio allowed automated tracing of the main 
dendritic branch and detection as well as classification of dendritic spines (Figure 12A-C, E) 
using the so-called Rayburst sampling algorithm (Rodriguez et al., 2008; Rodriguez et al., 
2006). Raburst sampling used multidirectional rays casting from the center of mass of a 3D 
object to its surface in order to compute precisely diameters, volumes and surface areas 
(Dumitriu et al., 2011; Rodriguez et al., 2008; Rodriguez et al., 2006). Spine volumetric 
measurements like spine head volumes (Figure 12F) used a 3D Rayburst algorithm 
(Rodriguez et al., 2006). Two-dimensional (2D) Raburst algorithms were used to analyze 
dendritic shaft diameter at each node (Rodriguez et al., 2006; Wearne et al., 2005), which is 
useful to estimate irregularities in branch diameters (Figure 12D), and to perform spine shape 
classifications (Rodriguez et al., 2008) (Figure 12E). Spines were classified according to the 
default values set in NeuronStudio (CNIC) into mushroom, stubby or thin (Figure 12B). 




shapes were distributed along the dendrite (Figure 12E and F) and basal dendritic segments 
were more regularly shaped in contrary to more distal parts, which showed some fluctuations 
as indicated by increased changes in radii per dendritic length (Figure 12D). Using this 
computational approach clearly showed, that precise detection of dendrites and spines and 
shape analyses was performable. Ongoing measurements will assess dendritic and spine 
alteraltions within demyelinated cerebral cortex. 
 
 
Figure 12  3D analysis of dendritric and spine shapes 
(A) Tracing of dendrites (green nodes) and spines (colored small circles) in deconvolved confocal 
images led to 3D reconstruction and analysis of spine density (C) and fluctuations in dendritic shaft 
radius (D) as function of distance to the soma using NeuronStudio. (B) Shape classification of spines 
and their densities (E) and head volumes (F) were automatically computed in NeuronStudio. Data 




4.8 Loss of dendritic spines and branches in the cortex of progressive MS cases 
Since synaptic loss has been shown in leukocortical lesions (Wegner et al., 2006), cortical 
dendrites were analyzed in autopsy specimen from chronic MS patients with a late disease-
stage focussing on the number of dendritic spines and branches and compared to dendrites in 
healthy controls (Figure 13). MS autopsy cases and controls are summarized in Table 3. Brain 
tissue containing cerebral cortex was dissected from the frontotemporal lobe (F2-3) of both 
hemispheres and tissue blocks were split into two parts and either processed for MBP staining 
to assess cortical demyelination or Golgi-Cox staining to study cortical dendrites (Figure 
13A). In two out of four MS patients cortical demyelinated lesions could be detected in the 
frontotemporal cortex specimen. A representative picture of such a human cortical lesion in 
comparison to NAGM and GM in healthy controls is shown in Figure 13B. On the basis of 
the adjacent MBP-stained sections, cortical neurons were classified as located within the 
lesion, at the lesion border or in NAGM. In Golgi-Cox impregnated sections neurons of the 
cortical layer IV-VI were chosen for image acquisition with a confocal laser scanning 
microscope (Figure 13C). Spines and branches were counted on 50 µm successive basal 
dendritic segments of the main dendritic branch from the neuronal soma in MS cases and 
healthy controls. Individual case spine counts are depicted in Figure 13D. Similar to the 
distribution of spine densities detected in mice, control specimen showed that the number of 
spines increased in relation to the distance to the soma with a continuous increase in spine 
number to distances of 150 µm to 200 µm from the soma and a slight reduction in longer 
distances.  
 
Table 3 MS and control cases 
MS cases Sex Age at death Disease duration Storage in 4% formalin 
1 female 44 years unknown 1 month 
2 female 51 years over 10 years (RRMS) 2 month 
3 male 55 years over 10 years 1.5 month 
4 male 51 years over 10 years 1.5 month 
  Mean age at death: 
50.3 years 
 Mean storage period: 
1.5 month 
Controls     
1 male 62 years no neurologic disease 2 month 
2 female 68 years no neurologic disease 1 month 
3 male 64 years no neurologic disease 1 month 
  Mean age at death:  
64.7 years 







Quantification of spine counts in MS patients revealed a decreased number of dendritic spines 
predominantly at longer distances to the soma in comparison to controls and the reduction in 
spine number was irrespective of neuronal localization within a demyelinated lesion including 
the lesion border or in NAGM. An analysis of combined data of all MS cases and controls 
indicated a significant reduction in the number of dendritic spines within cortical lesions or 
NAGM compared to controls in a two-way ANOVA (Figure 13E). The number of dendritic 
branches showed a significant trend for reduced branch numbers in a two-way ANOVA (post 
hoc test not significant) primary in shorter distances to the soma in MS patients. In all cases, 
the investigated dendrites had comparable dendritic width excluding varying spine numbers 
due to different dendritic sizes (Figure 13E). These results demonstrated a pronounced global 
dendritic pathology in progressive MS formed by reduced dendritic spine densities in neurons 
















Figure 13 Reduced densities of dendritic spines and branches in chronic MS 
(A) Autopsy tissue from MS patients and healthy controls was dissected as indicated and processed for 
MBP staining (B) or Golgi-Cox impregnation (C). (B) Note the cortical lesion in MS (lesion border is 
indicated by the dotted line, border between GM and WM is marked by the dashed line). (D) 
Quantification of the number of dendritic spines (red arrows in (C)) and branches (yellow arrows in 
(C)) in individual cases (analyzed number of dendrites per case is indicated in the graph). (E) 
Combined individual spine counts revealed a significant reduction in spine and branch density in MS 
but comparable dendritic width to controls. (D) Data are expressed as mean ± SD. (E) Data are shown 
as mean ± SEM (n = 3 controls, n = 4 MS NAGM, n = 2 MS lesion + border). For statistical analyses a 









5.1 Targeted cortical EAE in mice allows reproducible lesion induction within a 
defined anatomical area 
In the presented work an EAE mouse model targeting the cerebral cortex was established. The 
intracortical injection of a proinflammatory cytokine cocktail composed of TNF-α and IFN-γ 
in MOG-immunized BiozziABH and F1 hybrids generated from BiozziABH and mice on a 
C57BL6/J background triggered the formation of confluent demyelinated lesions in the 
cortical GM in a predetermined anatomical area, in a temporally well-defined manner and 
with reproducibility. 
Therefore, this model allows the precise investigation of pathomechanisms involved in lesion 
formation in the cortical GM which is in contrast to ‘conventional’ disseminated EAE models 
that rarely affect the brain or lesions occur randomly distributed in the GM (Girolamo et al., 
2011; Mangiardi et al., 2011; Merkler et al., 2006a; Pomeroy et al., 2008; Pomeroy et al., 
2005; Rasmussen et al., 2007; Storch et al., 2006). Moreover, the confluent demyelination 
with well-demarcated lesion borders induced in the here described model is in contrast to the 
myelin loss in cerebral cortices of ‘conventional’ EAE mice as demyelination is exemplified 
by reduced myelin density but confluent demyelinated areas are not measured (Girolamo et 
al., 2011; Mangiardi et al., 2011). Although cortical lesions were induced artificically, they 
reproduced the immunopathological nature characteristic for MS lesions. This is in contrast to 
toxin-induced models like the systemic administration of the copper chelator cuprizone. 
Cuprizone treatment lead to demyelination in defined anatomical areas like the cerebral cortex 
(Merkler et al., 2009; Skripuletz et al., 2008), however, this model triggers primary the death 
of mature oligodendrocytes and does not mimic the complex immunopathology of MS lesions 
(Skripuletz et al., 2011; Torkildsen et al., 2008). An important aspect of the here described 
targeted cortical EAE model was the functionality in BiozziABH mice and their F1 offsprings 
intercrossed with mice on a C57BL6/J background. Intercrossing of transgenic mice allows 
the use of reporter strains like the used mice that express EGFP in a subset of cortical neurons 
in this work. A striking phenomenon was the reproducible induction of primarily subpial 
lesions in the targeted cortical EAE mouse model sharing pathological hallmarks with MS. 
EAE lesions spread laterally as band-like demyelination extending from the pial surface of the 
brain mostly to cortical layer II and exhibited a well-demarcated lesion border. This induced 




(Lucchinetti et al., 2011) and chronic MS patients (Bo et al., 2003b; Peterson et al., 2001) as 
well as in the targeted cortical EAE rat model (Merkler et al., 2006b). Subpial lesions were 
the second most common cortical lesion type (accounted for a considerably proportion of 
about 34%) in early MS (Lucchinetti et al., 2011) and the most common cortical lesion type in 
chronic MS (Albert et al., 2007; Bo et al., 2003b; Giaccone et al., 2012; Kutzelnigg et al., 
2005; Peterson et al., 2001; Vercellino et al., 2005). The occurrence of almost only subpial 
lesions and nearly no intracortical or leukocortical lesions would be in favor for an intrinsic 
cortical demyelinating disease that can occur independently to WM lesions (Giaccone et al., 
2012; Kutzelnigg et al., 2005). The lesion distribution preferentially at subpial areas might 
also be explained by a reflow of intracerebral injected cytokines back through the injection 
trace to the surface of the brain, which can sometimes be observed during the stereotactic 
injection of the animals or during mechanical retraction of the capillary. Furthermore, it has 
been shown that intraparenchymal injected tracer spread along perivascular spaces to the 
surface of the brain and leaked into the CSF (Abbott, 2004), intracortical injected cytokines 
could diffuse equally. After reaching subpial areas, the cytokines might activate the BBB and 
affect BBB integrity to allow activated T cells and autoantibodies to enter the CNS 
parenchyma and lead to a localized inflammatory lesion in this area. Moreover, cortical 
demyelination is associated with meningeal inflammation (Choi et al., 2012; Howell et al., 
2011; Kutzelnigg et al., 2005; Lucchinetti et al., 2011; Magliozzi et al., 2007). Diffusion of 
pro-inflammatory cytokines from inflamed meninges could support cortical GM pathology 
from the surface of the brain (Magliozzi et al., 2010). Since the targeted EAE mouse model 
also showed meningeal inflammation (data not shown) cortical demyelination might be 
induced from cytokines released from the meninges. However, since control mice also 
showed meningeal inflammation, a sole cytokine-mediated mechanism from the meninges 
seems to be insufficient to induce demyelination. 
 
5.2 Active cortical demyelination and inflammation are transient and do not 
induce neuronal or axonal loss 
The induction of confluent demyelinated lesions in the cerebral cortex of MOG-immunized 
mice was accompanied by the development of anti-MOG autoantibody titers in sera and 
widespread but temporarily infiltration of T cells and activated macrophages/microglia in the 




The inflammatory character and composition of the here described cortical EAE lesions in 
mice reflect the highly inflammatory nature of cortical demyelinated lesions in early-stage 
MS patients, which also consists of activated microglia and a strong T cell inflammation 
(Lucchinetti et al., 2011). Furthermore, these findings are also in line with observations in the 
targeted cortical EAE rat model. Cortical demyelination accompanies a transient parenchymal 
T cell infiltration in a comparable range to the here presented model but exhibit 25% less 
activated macrophages/microglia three days after lesion induction. Inflammation resolves 
afterwards within two weeks (Merkler et al., 2006b). The profound clearance of inflammation 
in the targeted EAE mouse model might explain the differences in early disease-stage cortical 
lesions in MS patients, which are highly inflammatory (Lucchinetti et al., 2011), in 
comparison to chronic lesions in late-stage MS, which are less inflammatory (Bo et al., 
2003a; Peterson et al., 2001). This demonstrates that the targeted EAE mouse model reflects 
cortical lesions observed in early-stage MS patients and is useful to study underlying 
pathomechanisms. 
A striking aspect between the cytokine-injected cortices of EAE mice exhibiting 
demyelination and control mice without demyelination was the difference in reactive 
macrophage/microglia phenotypes. Generally, entire cortical hemispheres subjected to a 
lesion showed higher numbers of reactive macrophages/micrglia with remarkable more 
round/oval-shaped and especially foamy macrophages/micrglia compared to control cortices. 
Particular the presence of foamy macrophages/microglia in NAGM in the lower cortical 
layers indicate ongoing demyelination since these cells are associated with ingestion of 
myelin debris. According to this model, myelin-laden macrophages/microglia are described in 
the targeted cortical EAE of rats (Merkler et al., 2006b) and in active cortical lesions in early 
MS (Lucchinetti et al., 2011). Furthermore, the parenchymal distribution of particular 
round/oval-shaped macrophages/microglia and T cells in affected cortices may indicate an 
interaction between these cells. Infiltrating activated macrophages and reactive microglia 
could function as APC thereby triggering local reactivation of infiltrating MOG-specific T 
cells and propagation of the immune response. In turn, T cells could secrete soluble factors 
that stimulate macrophages/microglia and also exaggerate the disease (Jack et al., 2005). The 
presence of round/oval-shaped and foamy macrophages/microglia in lesioned hemispheres 
might indicate that these cells trigger the observed demyelination. Moreover, all reactive 
phenotypes could trigger tissue damage by production of toxic mediators or reactive oxygen 
or nitric oxide species (Jack et al., 2005). Next steps would be to further characterize the cell 




In addition to initiate CNS inflammation, encephalitogenic T cells are also required to disrupt 
the BBB allowing humoral immune factors like antibodies to penetrate the CNS parenchyma 
(Genain et al., 1995; Iglesias et al., 2001).  
In this work, mice were immunizated with recombinant MOG1-125 instead of MOG-peptide in 
order to elicit a strong MOG-specific antibody response. Peripheral immune priming against 
MOG was clearly required for the induction of cortical demyelinated lesions in the targeted 
EAE since mice treated with CFA alone did not reveal signs of cortical demyelination 
although they were subjected to an intracortical cytokine injection.  
Antibody and complement-mediated mechanisms in demyelination have been suggested in 
active MS lesions by the identification of immunoglobulin and complement deposition in a 
proportion of patients (Lucchinetti et al., 2000) and by detecting MOG autoantibodies in WM 
lesions of EAE and MS and their association with myelin damage (Genain et al., 1999; Raine 
et al., 1999). Furthermore, in vivo studies demonstrate that passively transferred MOG-
specific monoclonal autoantibodies enhance demyelination in rats that were previously treated 
with either MBP-specific T cells or MBP/CFA (Lassmann et al., 1988; Linington et al., 1988; 
Schluesener et al., 1987) and BiozziABH immunized with spinal cord homogenate (Morris-
Downes et al., 2002). These findings, together with the detection of high anti-MOG 
autoantibody titers as well as complement deposition in cortical lesions in targeted rat EAE 
(Merkler et al., 2006), suggest that the pathogenic effect observed in the here described model 
is an interplay between B cell derived MOG-specific autoantibodies, probably followed by 
complement activation, establishment of an autoaggressive T cell response and activation of 
macrophages/microglia. Macrophages/microglia might be activated by both, autoantibodies in 
combination with complement and T cells, which then trigger myelin destruction by secretion 
of toxic factors and phagocytosis of myelin debris. 
In the here described model, cortical lesion formation required in addition to the anti-MOG 
immune response the injection of the proinflammatory cytokines TNF-α and IFN-γ into the 
cortex. 
Both cytokines have been associated with lesion formation in EAE and MS (Steinman, 2001) 
and are detectable within active MS lesions (Hofman et al., 1989; Selmaj et al., 1991; 
Traugott and Lebon, 1988). They can activate cerebral endothelial cells, which are important 
components of the BBB, to express adhesion modelcules in order to trigger T cell arrest and 
migration into the CNS parenchyma and they can induce damage to the BBB by disorganizing 
cell-cell junctions (Minagar and Alexander, 2003). Most importantly, both cytokines attrack 




CNS (Kerschensteiner et al., 2004b; Merkler et al., 2006b). Since the half-life of the locally 
injected cytokine mixture into the cortex is unclear, the transient nature of the acute 
inflammatory demyelination observed in the here described model might be attributed to a 
short-lived effect of these cytokines. Therefore, it might conceivable to induce chronic 
demyelinated lesions by continuous intracortical delivery of these cytokines for a distinct time 
period. 
Furthermore, transient cortical demyelination did not result in axonal loss in subpial areas 
although remyelination was only efficient in about 50% of axons. Moreover, neuronal loss 
was not observed in the affected hemisphere at day three and week three after lesion 
induction. 
Axonal and neuronal preservation are in line with previous findings that shows indeed acute 
axonal damage as visualized by the accumulation of amyloid precursor protein in axons in 
areas of subpial demyelination and around inflamed vessels in rat cortex but this result not in 
a reduction of axonal density after remyelination and only single apoptotic neurons in 
demyelinated areas are detectable (Merkler et al., 2006b). Moreover, the majoriy of cortical 
lesions in early MS exhibit relative axonal preservation and only several plaques have focal 
neuronal injury seen by pyknotic neurons (Lucchinetti et al., 2011). Axonal preservation in 
the here described model might be due to the fast decline of inflammation since axonal 
pathology correlates with inflammation (Kuhlmann et al., 2002; Trapp et al., 1998).  
The future aim of the targeted EAE mouse model is the assessment of dendritic pathologies 
within demyelinated cortical lesions as well as in the surrounding NAGM. This approach 
needs high-resolution imaging of dendrites and dendritic spines, deconvolution and a 
computational 3D reconstruction (Dumitriu et al., 2011; Rodriguez et al., 2008; Rodriguez et 
al., 2006). The introduction of transgenic mice on a C57BL6/J background with fluorescently 
labeled single cortical neurons in the here used F1 hybrids allowed high-resolution imaging of 
dendrites, branches and dendritic spines using confocal laser scanning microscopy. 
Deconvolution and reconstruction of these neuronal structures allowed detailed analysis of 
dendritic shaft radii, spine densities and even spine shapes in addition to spine head volumes 
in an automated manner using NeuronStudio (CNIC). This method provides the basis for 
detecting even subtle changes as alterations in spine volumes or numbers of specific spine 
shapes or common changes in spine density. Furthermore, potential dendritic swellings can be 
analyzed by means of radii analysis along the dendrite. Dendritic alterations might represent 
pathological hallmarks in cerebral cortices of MS patients since synaptic loss can occur in 




in‘conventional’ EAE rat and mouse models in lumbosacral spinal cord tissue (Bannerman et 
al., 2005; Zhu et al., 2003) and spine loss is detectable in acute EAE on second dendritic 
branches of striatal neurons (Rossi et al., 2012). Dendritic abnormalities might contribute to 
clinical symptoms like neuropsychiatric deficits and therefore have to be studied in detail. 
 
5.3 Widespread but incomplete remyelination 
Although active demyelination in the here described model was observed as a transient loss of 
myelin and occurrence of foamy macrophages/microglia and T cell infiltrates in the range of 
days after cytokine injection, only partial remyelination could be detected after three weeks 
although axons remained preserved. 
In non-demyelintead cortex, myelin is regularly arranged and the proportion of myelinated 
axons in the cortical layer I+II detected in the targeted EAE mouse model in this work and 
cortical layer III in targeted EAE rat model is strikingly similar and is about 40% (Garea 
Rodriguez, 2010). The pattern of remyelinated fibers was diffuse in comparison to normal 
myelinated equal areas, which is in line with human remyelinated plaques (Bruck et al., 
2003). The extent of remyelination was in a similar range in the mouse model and rat model 
as about 40-50% of axons got remyelinated after a demyelinating event (Garea Rodriguez, 
2010). Although remyelination could be observed, it remained incomplete. The partial 
regenerative capacity however could not be attributed to axonal loss because axons remained 
preserved in the targeted EAE mouse model and axonal preservation is in line with findings in 
the rat (Garea Rodriguez, 2010; Merkler et al., 2006b). Furthermore, electron microscopic 
analysis reveals a thinner myelin sheath confirming that these fibers are remyelinated 
(Merkler et al., 2006b).  
The incomplete remyelination observed in mice might represent a stage, in which the 
regenerative process has not finished yet and a complete recovery would require longer time 
periods. However, the partial remyelination observed in the cortical EAE mouse model is in 
accordance with incomplete remyelination capacity frequently found in MS patients in WM 
and cortical GM (Albert et al., 2007; Bruck et al., 2003). Mechanisms involved in 
remyelination may differ in WM and GM lesions as cortical lesions remyelinate more 
efficient (Albert et al., 2007; Chang et al., 2012). The here established targeted cortical EAE 
could be extended to target additionally WM structures in order to compare directly the 





Capacity for endogenous cortical remyelination can be observed in MS irrespective of disease 
duration or age of the patients (Chang et al., 2012), however, chronic demyelinated lesions 
usually accumulate with disease progression (Kutzelnigg et al., 2005). Exhaustion of 
remyelination might be attributed to a lack of oligodendrocyte progenitor cells, failure of 
precursor cell recruitment including proliferation, migration and repopulation or disturbed 
differentiation and maturation to myelinating oligodendrocytes which is the best evident 
(Chang et al., 2002; Franklin and Ffrench-Constant, 2008; Kuhlmann et al., 2008). It would 
therefore be interesting to investigate in the here described model, whether remyelination 
efficiency can be promoted by different factors interfering with oligodendrocyte 
differentiation and maturation. Demyelination in cortical GM of rats shows a transient loss of 
oligodendrocytes but demyelinated areas are repopulated during remyelination (Merkler et al., 
2006b) and existing oligodenrocyte precursor cells show substantial proliferation (Garea 
Rodriguez, 2010). If this is also the case in the mouse remains unclear at state.  
 
5.4 Global dendritic spine loss in cortices of progressive MS patients 
Since the end of the 1990s, MS research has refocused on the pathology affecting neuronal 
structures in the CNS (Peterson et al., 2001; Trapp et al., 1998; Wegner et al., 2006) that 
might attributed to CNS atrophy (Siffrin et al., 2010) and irreversible neurologic disability 
(Trapp and Nave, 2008). 
In this work, cortical GM autopsy specimen from the frontotemporal lobe of the cerebrum 
were obtained from progressive MS patients and investigated for pathologic dendritic 
alterations. Interestingly, MS cortex showed a global reduction of dendritic spine density of 
neurons located in lower cortical layers in chronically demyelinated lesions as well as in the 
NAGM. Furthermore, dendrites in the cortical GM of MS patients were identified to trend for 
decreased branch numbers primarily in basal dendritic segments. 
The detailed spine analysis could be achieved by the combination of the neuronal 
impregnation technique Golgi-Cox, which is invaluable in its characteristic to stain randomly 
distributed single neurons in the network of indefinitely neurons on an almost clear 
background, with laser scanning confocal microscopy, which was applicable due to the 
reflective capacity of the dense metal particles within the neurons and allowed high-resolution 
imaging (Mancuso et al., 2012; Spiga et al., 2011; Tredici et al., 1993).  
Dendritic spine pathologies can be triggered from many conditions like progressive 




retardation, traumatic injury or deafferentitaion (Fiala et al., 2002). The latter, neuronal 
deafferentation, induces dendritic spine loss in the adult CNS that can be partial recovered by 
axonal sprouting and replacement of the lost afferent synaptic input (Cheng et al., 1997; 
Parnavelas et al., 1974). Therefore, damage or loss of projections, e.g. thalamocortical axons, 
may result in transsynaptic deafferentation and spine loss on neurons in the cortex. Since the 
thalamus has been associated with neuronal injury and loss in MS (Cifelli et al., 2002; 
Wylezinska et al., 2003), the here observed spine loss may in part be explained by 
neurodegenerative processes in other brain areas like the thalamus. Moreover, since 
thalamocortical projections connect many cortical areas, spine loss would not be restricted to 
a focal (lesioned) area, spine pathology would rather occur in a global manner as observed in 
the investigated chronic MS cortices. In addition, transected and damaged neurits have been 
described in both, WM and GM structures (Peterson et al., 2001; Trapp et al., 1998) that 
might contribute to a loss of synaptic transmission. In early disease-stage, damaged or lost 
connecting pathways might induce sprouting or remodeling of axonal connections 
(Kerschensteiner et al., 2004a), however, if regenerative capacities were exceeded a decline in 
spine density would persist. 
As mentioned above, spine abnormalities are a common feature in neurodegenerative or 
neuropsychiatric diseases. Spine densities are reduced on cortical neurons in Alzheimer’s 
disease (Fiala et al., 2002; Mavroudis et al., 2011) and schizophrenia (Garey et al., 1998), but 
are increased in autism spectrum disorders (Hutsler and Zhang, 2010). Furthermore, a 
neocortical synapse loss is correlated with cognitive deficits in Alzheimer’s disease (Terry et 
al., 1991). Since cognitive deficits are also commonly seen in MS (Amato et al., 2006), the 
here identified global dendritic spine pathology may partially account for the neuropsychiatric 
deficits in progressive MS. 
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6 SUMMARY AND CONCLUSIONS 
In the presented work a targeted cortical EAE mouse model was established and 
characterized. Furthermore, dendritic pathology was investigated in the cortical GM of 
chronic MS patients. 
Cortical demyelinated lesions were induced in EAE mice by the targeted injection of 
proinflammatory cytokines into the cerebral cortex. Histological evaluation revealed 
extensive subpial demyelination and widespread inflammation composed of T cells and 
activated macrophages/microglia three days after lesion induction. Within three weeks 
inflammation decreased profoundly and lesions remyelinated to a major extent although 
myelin density and proportion of myelinated axons did not again reach levels of untreated 
animals. In this acute model axonal and neuronal loss could not be observed in the affected 
cortex at three days or three weeks after lesion induction. Furthermore, a method was 
established that allows precise investigation of abnormalities in dendrites and dendritic spines 
in mice. 
A global reduction of dendritic spines in neurons of the lower cortical layers could be 
identified as a pathological hallmark of chronically demyelinated lesions as well as the 
surrounding NAGM in autopsy specimen of progressive MS patients. 
Targeted cortical EAE lesion in the mouse shared several pathological hallmarks with active 
lesions in the cortical GM of early-stage MS patients. Neurodegenerative processes observed 
in chronic MS lesions or surrounding NAGM were not reflected by this model. Therefore, the 
targeted cortical EAE mouse model mimics cortical lesions rather in early-stage MS patients 
and is suitable to study pathomechanisms occurring early in the cerebral cortex. 
The global reduction of dendritic spines in the cerebral cortex of progressive MS is a new 
neurodegenerative feature that might be attributed to neuropsychological deficits and should 
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